ZA200602358B - Derivatives of hydroxamic acid as metalloproteinase inhibitors - Google Patents
Derivatives of hydroxamic acid as metalloproteinase inhibitors Download PDFInfo
- Publication number
- ZA200602358B ZA200602358B ZA200602358A ZA200602358A ZA200602358B ZA 200602358 B ZA200602358 B ZA 200602358B ZA 200602358 A ZA200602358 A ZA 200602358A ZA 200602358 A ZA200602358 A ZA 200602358A ZA 200602358 B ZA200602358 B ZA 200602358B
- Authority
- ZA
- South Africa
- Prior art keywords
- phenyl
- hydroxy
- carbonyl
- hexanoic acid
- acid hydroxyamide
- Prior art date
Links
- 239000003475 metalloproteinase inhibitor Substances 0.000 title claims description 3
- 239000002253 acid Substances 0.000 title description 6
- NEAQRZUHTPSBBM-UHFFFAOYSA-N 2-hydroxy-3,3-dimethyl-7-nitro-4h-isoquinolin-1-one Chemical class C1=C([N+]([O-])=O)C=C2C(=O)N(O)C(C)(C)CC2=C1 NEAQRZUHTPSBBM-UHFFFAOYSA-N 0.000 title description 4
- ZXKINMCYCKHYFR-UHFFFAOYSA-N aminooxidanide Chemical compound [O-]N ZXKINMCYCKHYFR-UHFFFAOYSA-N 0.000 claims description 62
- 150000001875 compounds Chemical class 0.000 claims description 60
- 125000000217 alkyl group Chemical group 0.000 claims description 32
- -1 methoxy, ethoxy, trifluoromethoxy, methyl Chemical group 0.000 claims description 22
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 19
- 229910052757 nitrogen Inorganic materials 0.000 claims description 17
- PXQLVRUNWNTZOS-UHFFFAOYSA-N sulfanyl Chemical class [SH] PXQLVRUNWNTZOS-UHFFFAOYSA-N 0.000 claims description 16
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 14
- 238000000034 method Methods 0.000 claims description 14
- 201000010099 disease Diseases 0.000 claims description 13
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 13
- 229910052739 hydrogen Inorganic materials 0.000 claims description 13
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 13
- 150000003839 salts Chemical class 0.000 claims description 13
- 125000001072 heteroaryl group Chemical group 0.000 claims description 12
- 125000000623 heterocyclic group Chemical group 0.000 claims description 12
- 239000001257 hydrogen Substances 0.000 claims description 12
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 12
- 125000002837 carbocyclic group Chemical group 0.000 claims description 11
- 238000002360 preparation method Methods 0.000 claims description 10
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 9
- 125000005843 halogen group Chemical group 0.000 claims description 9
- 125000006413 ring segment Chemical group 0.000 claims description 9
- 125000001424 substituent group Chemical group 0.000 claims description 9
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 8
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 8
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 claims description 8
- 125000003545 alkoxy group Chemical group 0.000 claims description 7
- 229910052799 carbon Inorganic materials 0.000 claims description 7
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 7
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims description 7
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 7
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 7
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 6
- 201000006417 multiple sclerosis Diseases 0.000 claims description 6
- 125000004076 pyridyl group Chemical group 0.000 claims description 6
- 208000006673 asthma Diseases 0.000 claims description 5
- 206010006451 bronchitis Diseases 0.000 claims description 5
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 5
- 239000012453 solvate Substances 0.000 claims description 5
- 125000001544 thienyl group Chemical group 0.000 claims description 5
- GVNVAWHJIKLAGL-UHFFFAOYSA-N 2-(cyclohexen-1-yl)cyclohexan-1-one Chemical compound O=C1CCCCC1C1=CCCCC1 GVNVAWHJIKLAGL-UHFFFAOYSA-N 0.000 claims description 4
- 101150065749 Churc1 gene Proteins 0.000 claims description 4
- 201000003883 Cystic fibrosis Diseases 0.000 claims description 4
- 102100038239 Protein Churchill Human genes 0.000 claims description 4
- 125000004414 alkyl thio group Chemical group 0.000 claims description 4
- 125000001309 chloro group Chemical group Cl* 0.000 claims description 4
- 208000019425 cirrhosis of liver Diseases 0.000 claims description 4
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims description 4
- 125000002541 furyl group Chemical group 0.000 claims description 4
- 230000004968 inflammatory condition Effects 0.000 claims description 4
- 230000008569 process Effects 0.000 claims description 4
- 125000000714 pyrimidinyl group Chemical group 0.000 claims description 4
- 206010016654 Fibrosis Diseases 0.000 claims description 3
- 125000001246 bromo group Chemical group Br* 0.000 claims description 3
- 230000004761 fibrosis Effects 0.000 claims description 3
- 230000003176 fibrotic effect Effects 0.000 claims description 3
- 125000001153 fluoro group Chemical group F* 0.000 claims description 3
- 208000007565 gingivitis Diseases 0.000 claims description 3
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims description 3
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 claims description 3
- 150000002825 nitriles Chemical class 0.000 claims description 3
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 3
- 201000008482 osteoarthritis Diseases 0.000 claims description 3
- 125000004193 piperazinyl group Chemical group 0.000 claims description 3
- 125000003386 piperidinyl group Chemical group 0.000 claims description 3
- 208000037803 restenosis Diseases 0.000 claims description 3
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 3
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 3
- 125000002941 2-furyl group Chemical group O1C([*])=C([H])C([H])=C1[H] 0.000 claims description 2
- 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 claims description 2
- 125000000175 2-thienyl group Chemical group S1C([*])=C([H])C([H])=C1[H] 0.000 claims description 2
- 125000003682 3-furyl group Chemical group O1C([H])=C([*])C([H])=C1[H] 0.000 claims description 2
- 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 claims description 2
- 125000001541 3-thienyl group Chemical group S1C([H])=C([*])C([H])=C1[H] 0.000 claims description 2
- 125000000339 4-pyridyl group Chemical group N1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 claims description 2
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 claims description 2
- 206010053555 Arthritis bacterial Diseases 0.000 claims description 2
- 208000023275 Autoimmune disease Diseases 0.000 claims description 2
- 208000006386 Bone Resorption Diseases 0.000 claims description 2
- 206010007572 Cardiac hypertrophy Diseases 0.000 claims description 2
- 208000006029 Cardiomegaly Diseases 0.000 claims description 2
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims description 2
- 206010009900 Colitis ulcerative Diseases 0.000 claims description 2
- 208000011231 Crohn disease Diseases 0.000 claims description 2
- 206010012438 Dermatitis atopic Diseases 0.000 claims description 2
- 206010014989 Epidermolysis bullosa Diseases 0.000 claims description 2
- 208000009329 Graft vs Host Disease Diseases 0.000 claims description 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 2
- 208000004575 Infectious Arthritis Diseases 0.000 claims description 2
- 206010061218 Inflammation Diseases 0.000 claims description 2
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims description 2
- 206010027476 Metastases Diseases 0.000 claims description 2
- 208000036110 Neuroinflammatory disease Diseases 0.000 claims description 2
- 201000004681 Psoriasis Diseases 0.000 claims description 2
- 201000001263 Psoriatic Arthritis Diseases 0.000 claims description 2
- 208000036824 Psoriatic arthropathy Diseases 0.000 claims description 2
- 208000001647 Renal Insufficiency Diseases 0.000 claims description 2
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 claims description 2
- 208000021386 Sjogren Syndrome Diseases 0.000 claims description 2
- 206010052779 Transplant rejections Diseases 0.000 claims description 2
- 208000025865 Ulcer Diseases 0.000 claims description 2
- 206010064996 Ulcerative keratitis Diseases 0.000 claims description 2
- 201000000028 adult respiratory distress syndrome Diseases 0.000 claims description 2
- 125000002947 alkylene group Chemical group 0.000 claims description 2
- 201000008937 atopic dermatitis Diseases 0.000 claims description 2
- 230000024279 bone resorption Effects 0.000 claims description 2
- 229910052791 calcium Inorganic materials 0.000 claims description 2
- 210000000845 cartilage Anatomy 0.000 claims description 2
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims description 2
- 230000003412 degenerative effect Effects 0.000 claims description 2
- 230000002496 gastric effect Effects 0.000 claims description 2
- 208000024908 graft versus host disease Diseases 0.000 claims description 2
- 230000002757 inflammatory effect Effects 0.000 claims description 2
- 230000004054 inflammatory process Effects 0.000 claims description 2
- 201000006334 interstitial nephritis Diseases 0.000 claims description 2
- 230000009545 invasion Effects 0.000 claims description 2
- 208000017169 kidney disease Diseases 0.000 claims description 2
- 201000006370 kidney failure Diseases 0.000 claims description 2
- 210000000653 nervous system Anatomy 0.000 claims description 2
- 201000001119 neuropathy Diseases 0.000 claims description 2
- 230000007823 neuropathy Effects 0.000 claims description 2
- 201000001245 periodontitis Diseases 0.000 claims description 2
- 208000033808 peripheral neuropathy Diseases 0.000 claims description 2
- 125000000719 pyrrolidinyl group Chemical group 0.000 claims description 2
- 238000001959 radiotherapy Methods 0.000 claims description 2
- 230000037390 scarring Effects 0.000 claims description 2
- 201000001223 septic arthritis Diseases 0.000 claims description 2
- 125000003107 substituted aryl group Chemical group 0.000 claims description 2
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 2
- 230000009466 transformation Effects 0.000 claims description 2
- 125000004306 triazinyl group Chemical group 0.000 claims description 2
- 230000004614 tumor growth Effects 0.000 claims description 2
- 230000036269 ulceration Effects 0.000 claims description 2
- 150000002431 hydrogen Chemical class 0.000 claims 2
- 125000006297 carbonyl amino group Chemical group [H]N([*:2])C([*:1])=O 0.000 claims 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 1
- 125000000896 monocarboxylic acid group Chemical group 0.000 claims 1
- 150000002500 ions Chemical class 0.000 description 30
- 239000011734 sodium Substances 0.000 description 15
- 102000002274 Matrix Metalloproteinases Human genes 0.000 description 12
- 108010000684 Matrix Metalloproteinases Proteins 0.000 description 12
- 238000005160 1H NMR spectroscopy Methods 0.000 description 11
- 108010015302 Matrix metalloproteinase-9 Proteins 0.000 description 11
- 102100030412 Matrix metalloproteinase-9 Human genes 0.000 description 9
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 9
- 125000004432 carbon atom Chemical group C* 0.000 description 9
- 239000003814 drug Substances 0.000 description 9
- 230000005764 inhibitory process Effects 0.000 description 9
- 239000002904 solvent Substances 0.000 description 9
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 8
- 125000003118 aryl group Chemical group 0.000 description 8
- 125000005842 heteroatom Chemical group 0.000 description 8
- 239000011541 reaction mixture Substances 0.000 description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 6
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 6
- 239000000203 mixture Substances 0.000 description 6
- 230000002829 reductive effect Effects 0.000 description 6
- 238000011282 treatment Methods 0.000 description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 5
- 239000011575 calcium Substances 0.000 description 5
- 229910052760 oxygen Inorganic materials 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 239000000725 suspension Substances 0.000 description 5
- 102000029816 Collagenase Human genes 0.000 description 4
- 108060005980 Collagenase Proteins 0.000 description 4
- 239000012267 brine Substances 0.000 description 4
- 125000004122 cyclic group Chemical group 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 239000003112 inhibitor Substances 0.000 description 4
- 125000002950 monocyclic group Chemical group 0.000 description 4
- 239000003921 oil Substances 0.000 description 4
- 235000019198 oils Nutrition 0.000 description 4
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 4
- 108091007196 stromelysin Proteins 0.000 description 4
- 239000006188 syrup Substances 0.000 description 4
- 235000020357 syrup Nutrition 0.000 description 4
- 239000003981 vehicle Substances 0.000 description 4
- 102100026802 72 kDa type IV collagenase Human genes 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 3
- 108010010803 Gelatin Proteins 0.000 description 3
- 102000000380 Matrix Metalloproteinase 1 Human genes 0.000 description 3
- 108010016113 Matrix Metalloproteinase 1 Proteins 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 125000004429 atom Chemical group 0.000 description 3
- 125000000392 cycloalkenyl group Chemical group 0.000 description 3
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 3
- 238000003818 flash chromatography Methods 0.000 description 3
- 229920000159 gelatin Polymers 0.000 description 3
- 235000019322 gelatine Nutrition 0.000 description 3
- 235000011852 gelatine desserts Nutrition 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 239000003755 preservative agent Substances 0.000 description 3
- 238000011321 prophylaxis Methods 0.000 description 3
- 239000000600 sorbitol Substances 0.000 description 3
- 235000010356 sorbitol Nutrition 0.000 description 3
- 229910052717 sulfur Inorganic materials 0.000 description 3
- 239000003826 tablet Substances 0.000 description 3
- 230000000699 topical effect Effects 0.000 description 3
- FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 description 2
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 2
- 102100027995 Collagenase 3 Human genes 0.000 description 2
- 206010014561 Emphysema Diseases 0.000 description 2
- 102000013382 Gelatinases Human genes 0.000 description 2
- 108010026132 Gelatinases Proteins 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 2
- 240000007472 Leucaena leucocephala Species 0.000 description 2
- WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 102100030417 Matrilysin Human genes 0.000 description 2
- 108090000855 Matrilysin Proteins 0.000 description 2
- 108010076557 Matrix Metalloproteinase 14 Proteins 0.000 description 2
- 108010016165 Matrix Metalloproteinase 2 Proteins 0.000 description 2
- 102000001776 Matrix metalloproteinase-9 Human genes 0.000 description 2
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 2
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
- 229940124639 Selective inhibitor Drugs 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- 102100030416 Stromelysin-1 Human genes 0.000 description 2
- 102100028848 Stromelysin-2 Human genes 0.000 description 2
- 102100028847 Stromelysin-3 Human genes 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 125000002723 alicyclic group Chemical group 0.000 description 2
- 125000003342 alkenyl group Chemical group 0.000 description 2
- 150000001408 amides Chemical class 0.000 description 2
- 150000001412 amines Chemical class 0.000 description 2
- 239000012298 atmosphere Substances 0.000 description 2
- 239000002585 base Substances 0.000 description 2
- 229910052792 caesium Inorganic materials 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 230000008878 coupling Effects 0.000 description 2
- 238000010168 coupling process Methods 0.000 description 2
- 238000005859 coupling reaction Methods 0.000 description 2
- 239000006071 cream Substances 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N diphenyl Chemical compound C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 description 2
- 235000019441 ethanol Nutrition 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 150000002430 hydrocarbons Chemical group 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 239000002687 nonaqueous vehicle Substances 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- 239000012044 organic layer Substances 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 description 2
- WYURNTSHIVDZCO-UHFFFAOYSA-N tetrahydrofuran Substances C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical compound OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 1
- 125000004502 1,2,3-oxadiazolyl group Chemical group 0.000 description 1
- 125000004529 1,2,3-triazinyl group Chemical group N1=NN=C(C=C1)* 0.000 description 1
- 125000001399 1,2,3-triazolyl group Chemical group N1N=NC(=C1)* 0.000 description 1
- 125000004504 1,2,4-oxadiazolyl group Chemical group 0.000 description 1
- JCIIKRHCWVHVFF-UHFFFAOYSA-N 1,2,4-thiadiazol-5-amine;hydrochloride Chemical compound Cl.NC1=NC=NS1 JCIIKRHCWVHVFF-UHFFFAOYSA-N 0.000 description 1
- 125000004530 1,2,4-triazinyl group Chemical group N1=NC(=NC=C1)* 0.000 description 1
- 125000001376 1,2,4-triazolyl group Chemical group N1N=C(N=C1)* 0.000 description 1
- 125000004506 1,2,5-oxadiazolyl group Chemical group 0.000 description 1
- 125000001781 1,3,4-oxadiazolyl group Chemical group 0.000 description 1
- 125000004317 1,3,5-triazin-2-yl group Chemical group [H]C1=NC(*)=NC([H])=N1 0.000 description 1
- PVOAHINGSUIXLS-UHFFFAOYSA-N 1-Methylpiperazine Chemical compound CN1CCNCC1 PVOAHINGSUIXLS-UHFFFAOYSA-N 0.000 description 1
- WVUYYXUATWMVIT-UHFFFAOYSA-N 1-bromo-4-ethoxybenzene Chemical compound CCOC1=CC=C(Br)C=C1 WVUYYXUATWMVIT-UHFFFAOYSA-N 0.000 description 1
- 125000004973 1-butenyl group Chemical group C(=CCC)* 0.000 description 1
- FPIRBHDGWMWJEP-UHFFFAOYSA-N 1-hydroxy-7-azabenzotriazole Chemical compound C1=CN=C2N(O)N=NC2=C1 FPIRBHDGWMWJEP-UHFFFAOYSA-N 0.000 description 1
- DFPYXQYWILNVAU-UHFFFAOYSA-N 1-hydroxybenzotriazole Chemical compound C1=CC=C2N(O)N=NC2=C1.C1=CC=C2N(O)N=NC2=C1 DFPYXQYWILNVAU-UHFFFAOYSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- HEWZVZIVELJPQZ-UHFFFAOYSA-N 2,2-dimethoxypropane Chemical compound COC(C)(C)OC HEWZVZIVELJPQZ-UHFFFAOYSA-N 0.000 description 1
- VKUYLANQOAKALN-UHFFFAOYSA-N 2-[benzyl-(4-methoxyphenyl)sulfonylamino]-n-hydroxy-4-methylpentanamide Chemical compound C1=CC(OC)=CC=C1S(=O)(=O)N(C(CC(C)C)C(=O)NO)CC1=CC=CC=C1 VKUYLANQOAKALN-UHFFFAOYSA-N 0.000 description 1
- 125000004974 2-butenyl group Chemical group C(C=CC)* 0.000 description 1
- 125000006022 2-methyl-2-propenyl group Chemical group 0.000 description 1
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 1
- 101710151806 72 kDa type IV collagenase Proteins 0.000 description 1
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 1
- 235000019489 Almond oil Nutrition 0.000 description 1
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- GHXZTYHSJHQHIJ-UHFFFAOYSA-N Chlorhexidine Chemical compound C=1C=C(Cl)C=CC=1NC(N)=NC(N)=NCCCCCCN=C(N)N=C(N)NC1=CC=C(Cl)C=C1 GHXZTYHSJHQHIJ-UHFFFAOYSA-N 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 108050005238 Collagenase 3 Proteins 0.000 description 1
- 229910021591 Copper(I) chloride Inorganic materials 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- BWLUMTFWVZZZND-UHFFFAOYSA-N Dibenzylamine Chemical compound C=1C=CC=CC=1CNCC1=CC=CC=C1 BWLUMTFWVZZZND-UHFFFAOYSA-N 0.000 description 1
- QXNVGIXVLWOKEQ-UHFFFAOYSA-N Disodium Chemical compound [Na][Na] QXNVGIXVLWOKEQ-UHFFFAOYSA-N 0.000 description 1
- 239000004150 EU approved colour Substances 0.000 description 1
- 102000005593 Endopeptidases Human genes 0.000 description 1
- 108010059378 Endopeptidases Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical class Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- AVXURJPOCDRRFD-UHFFFAOYSA-N Hydroxylamine Chemical compound ON AVXURJPOCDRRFD-UHFFFAOYSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 description 1
- 229930064664 L-arginine Natural products 0.000 description 1
- 235000014852 L-arginine Nutrition 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 229940124761 MMP inhibitor Drugs 0.000 description 1
- 235000019759 Maize starch Nutrition 0.000 description 1
- 108010076497 Matrix Metalloproteinase 10 Proteins 0.000 description 1
- 108010076502 Matrix Metalloproteinase 11 Proteins 0.000 description 1
- 108010076503 Matrix Metalloproteinase 13 Proteins 0.000 description 1
- 108010016160 Matrix Metalloproteinase 3 Proteins 0.000 description 1
- 102100030216 Matrix metalloproteinase-14 Human genes 0.000 description 1
- 102000036436 Metzincins Human genes 0.000 description 1
- 108091007161 Metzincins Proteins 0.000 description 1
- 101150101095 Mmp12 gene Proteins 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- HTLZVHNRZJPSMI-UHFFFAOYSA-N N-ethylpiperidine Chemical compound CCN1CCCCC1 HTLZVHNRZJPSMI-UHFFFAOYSA-N 0.000 description 1
- MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 208000012902 Nervous system disease Diseases 0.000 description 1
- 208000025966 Neurological disease Diseases 0.000 description 1
- 102100030411 Neutrophil collagenase Human genes 0.000 description 1
- 101710118230 Neutrophil collagenase Proteins 0.000 description 1
- 102000056189 Neutrophil collagenases Human genes 0.000 description 1
- 108030001564 Neutrophil collagenases Proteins 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical class [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 1
- 102000016611 Proteoglycans Human genes 0.000 description 1
- 108010067787 Proteoglycans Proteins 0.000 description 1
- 241000253387 Rhodobiaceae Species 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 239000004141 Sodium laurylsulphate Substances 0.000 description 1
- 208000014151 Stomatognathic disease Diseases 0.000 description 1
- 101710108790 Stromelysin-1 Proteins 0.000 description 1
- 101710108792 Stromelysin-2 Proteins 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- 102000018594 Tumour necrosis factor Human genes 0.000 description 1
- 108050007852 Tumour necrosis factor Proteins 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 150000008044 alkali metal hydroxides Chemical class 0.000 description 1
- 229910001860 alkaline earth metal hydroxide Inorganic materials 0.000 description 1
- 125000003282 alkyl amino group Chemical group 0.000 description 1
- 239000008168 almond oil Substances 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 235000019270 ammonium chloride Nutrition 0.000 description 1
- 230000003444 anaesthetic effect Effects 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 239000008135 aqueous vehicle Substances 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 239000003899 bactericide agent Substances 0.000 description 1
- 229910052788 barium Inorganic materials 0.000 description 1
- DSAJWYNOEDNPEQ-UHFFFAOYSA-N barium atom Chemical compound [Ba] DSAJWYNOEDNPEQ-UHFFFAOYSA-N 0.000 description 1
- 229960000686 benzalkonium chloride Drugs 0.000 description 1
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 description 1
- 125000004618 benzofuryl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid group Chemical group C(C1=CC=CC=C1)(=O)O WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 description 1
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 description 1
- 125000003354 benzotriazolyl group Chemical group N1N=NC2=C1C=CC=C2* 0.000 description 1
- 125000004541 benzoxazolyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 description 1
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 1
- 125000002619 bicyclic group Chemical group 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 235000010290 biphenyl Nutrition 0.000 description 1
- 239000004305 biphenyl Substances 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000006172 buffering agent Substances 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 125000000609 carbazolyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3NC12)* 0.000 description 1
- 125000004452 carbocyclyl group Chemical group 0.000 description 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
- 150000001735 carboxylic acids Chemical class 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 229960003260 chlorhexidine Drugs 0.000 description 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
- 229960001231 choline Drugs 0.000 description 1
- 208000037976 chronic inflammation Diseases 0.000 description 1
- 208000037893 chronic inflammatory disorder Diseases 0.000 description 1
- 235000019504 cigarettes Nutrition 0.000 description 1
- 125000005390 cinnolyl group Chemical group N1=NC(=CC2=CC=CC=C12)* 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 239000003240 coconut oil Substances 0.000 description 1
- 235000019864 coconut oil Nutrition 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- OXBLHERUFWYNTN-UHFFFAOYSA-M copper(I) chloride Chemical compound [Cu]Cl OXBLHERUFWYNTN-UHFFFAOYSA-M 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- WZHCOOQXZCIUNC-UHFFFAOYSA-N cyclandelate Chemical class C1C(C)(C)CC(C)CC1OC(=O)C(O)C1=CC=CC=C1 WZHCOOQXZCIUNC-UHFFFAOYSA-N 0.000 description 1
- 125000001047 cyclobutenyl group Chemical group C1(=CCC1)* 0.000 description 1
- 125000001162 cycloheptenyl group Chemical group C1(=CCCCCC1)* 0.000 description 1
- 125000000596 cyclohexenyl group Chemical group C1(=CCCCC1)* 0.000 description 1
- 125000000522 cyclooctenyl group Chemical group C1(=CCCCCCC1)* 0.000 description 1
- 125000002433 cyclopentenyl group Chemical group C1(=CCCC1)* 0.000 description 1
- 125000000298 cyclopropenyl group Chemical group [H]C1=C([H])C1([H])* 0.000 description 1
- 238000010511 deprotection reaction Methods 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- UXGNZZKBCMGWAZ-UHFFFAOYSA-N dimethylformamide dmf Chemical compound CN(C)C=O.CN(C)C=O UXGNZZKBCMGWAZ-UHFFFAOYSA-N 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 239000000890 drug combination Substances 0.000 description 1
- 239000008157 edible vegetable oil Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 229940066758 endopeptidases Drugs 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000003925 fat Substances 0.000 description 1
- 235000019197 fats Nutrition 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 150000003948 formamides Chemical class 0.000 description 1
- 239000000417 fungicide Substances 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000003193 general anesthetic agent Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 235000001727 glucose Nutrition 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 150000004677 hydrates Chemical class 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N hydrochloric acid Substances Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- 229960003943 hypromellose Drugs 0.000 description 1
- 125000002883 imidazolyl group Chemical group 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 125000001041 indolyl group Chemical group 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 125000005990 isobenzothienyl group Chemical group 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000000904 isoindolyl group Chemical group C=1(NC=C2C=CC=CC12)* 0.000 description 1
- 125000005956 isoquinolyl group Chemical group 0.000 description 1
- 125000001786 isothiazolyl group Chemical group 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 125000005647 linker group Chemical group 0.000 description 1
- YNESATAKKCNGOF-UHFFFAOYSA-N lithium bis(trimethylsilyl)amide Chemical compound [Li+].C[Si](C)(C)[N-][Si](C)(C)C YNESATAKKCNGOF-UHFFFAOYSA-N 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- VTHJTEIRLNZDEV-UHFFFAOYSA-L magnesium dihydroxide Chemical class [OH-].[OH-].[Mg+2] VTHJTEIRLNZDEV-UHFFFAOYSA-L 0.000 description 1
- 235000012254 magnesium hydroxide Nutrition 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- CSNNHWWHGAXBCP-UHFFFAOYSA-L magnesium sulphate Substances [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 1
- 235000019341 magnesium sulphate Nutrition 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- BCVXHSPFUWZLGQ-UHFFFAOYSA-N mecn acetonitrile Chemical compound CC#N.CC#N BCVXHSPFUWZLGQ-UHFFFAOYSA-N 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- ITALFCPQCUCBBK-UHFFFAOYSA-N n,2-dihydroxyhexanamide Chemical compound CCCCC(O)C(=O)NO ITALFCPQCUCBBK-UHFFFAOYSA-N 0.000 description 1
- 125000001280 n-hexyl group Chemical group C(CCCCC)* 0.000 description 1
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000003506 n-propoxy group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])O* 0.000 description 1
- 125000004593 naphthyridinyl group Chemical group N1=C(C=CC2=CC=CN=C12)* 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 125000002868 norbornyl group Chemical group C12(CCC(CC1)C2)* 0.000 description 1
- 229940006093 opthalmologic coloring agent diagnostic Drugs 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 125000002971 oxazolyl group Chemical group 0.000 description 1
- 125000004043 oxo group Chemical group O=* 0.000 description 1
- 239000001301 oxygen Chemical group 0.000 description 1
- 239000003182 parenteral nutrition solution Substances 0.000 description 1
- IZUPBVBPLAPZRR-UHFFFAOYSA-N pentachloro-phenol Natural products OC1=C(Cl)C(Cl)=C(Cl)C(Cl)=C1Cl IZUPBVBPLAPZRR-UHFFFAOYSA-N 0.000 description 1
- 238000010647 peptide synthesis reaction Methods 0.000 description 1
- 208000028169 periodontal disease Diseases 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 229940096826 phenylmercuric acetate Drugs 0.000 description 1
- UYWQUFXKFGHYNT-UHFFFAOYSA-N phenylmethyl ester of formic acid Natural products O=COCC1=CC=CC=C1 UYWQUFXKFGHYNT-UHFFFAOYSA-N 0.000 description 1
- 125000003170 phenylsulfonyl group Chemical group C1(=CC=CC=C1)S(=O)(=O)* 0.000 description 1
- 125000004592 phthalazinyl group Chemical group C1(=NN=CC2=CC=CC=C12)* 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000011118 potassium hydroxide Nutrition 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 238000002953 preparative HPLC Methods 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 239000000651 prodrug Substances 0.000 description 1
- 229940002612 prodrug Drugs 0.000 description 1
- 230000000770 proinflammatory effect Effects 0.000 description 1
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
- 235000013772 propylene glycol Nutrition 0.000 description 1
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 1
- 125000001042 pteridinyl group Chemical group N1=C(N=CC2=NC=CN=C12)* 0.000 description 1
- 125000000561 purinyl group Chemical group N1=C(N=C2N=CNC2=C1)* 0.000 description 1
- 125000003226 pyrazolyl group Chemical group 0.000 description 1
- 125000000168 pyrrolyl group Chemical group 0.000 description 1
- 125000005493 quinolyl group Chemical group 0.000 description 1
- 125000001567 quinoxalinyl group Chemical group N1=C(C=NC2=CC=CC=C12)* 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 238000004366 reverse phase liquid chromatography Methods 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 229930195734 saturated hydrocarbon Natural products 0.000 description 1
- 239000012047 saturated solution Substances 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 239000000779 smoke Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- HRZFUMHJMZEROT-UHFFFAOYSA-L sodium disulfite Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])(=O)=O HRZFUMHJMZEROT-UHFFFAOYSA-L 0.000 description 1
- 235000011121 sodium hydroxide Nutrition 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 239000004296 sodium metabisulphite Substances 0.000 description 1
- 235000010262 sodium metabisulphite Nutrition 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 229940075582 sorbic acid Drugs 0.000 description 1
- WPLOVIFNBMNBPD-ATHMIXSHSA-N subtilin Chemical compound CC1SCC(NC2=O)C(=O)NC(CC(N)=O)C(=O)NC(C(=O)NC(CCCCN)C(=O)NC(C(C)CC)C(=O)NC(=C)C(=O)NC(CCCCN)C(O)=O)CSC(C)C2NC(=O)C(CC(C)C)NC(=O)C1NC(=O)C(CCC(N)=O)NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C1NC(=O)C(=C/C)/NC(=O)C(CCC(N)=O)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)CNC(=O)C(NC(=O)C(NC(=O)C2NC(=O)CNC(=O)C3CCCN3C(=O)C(NC(=O)C3NC(=O)C(CC(C)C)NC(=O)C(=C)NC(=O)C(CCC(O)=O)NC(=O)C(NC(=O)C(CCCCN)NC(=O)C(N)CC=4C5=CC=CC=C5NC=4)CSC3)C(C)SC2)C(C)C)C(C)SC1)CC1=CC=CC=C1 WPLOVIFNBMNBPD-ATHMIXSHSA-N 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 239000001117 sulphuric acid Substances 0.000 description 1
- 235000011149 sulphuric acid Nutrition 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000002278 tabletting lubricant Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- WHRNULOCNSKMGB-UHFFFAOYSA-N tetrahydrofuran thf Chemical compound C1CCOC1.C1CCOC1 WHRNULOCNSKMGB-UHFFFAOYSA-N 0.000 description 1
- 125000003831 tetrazolyl group Chemical group 0.000 description 1
- WROMPOXWARCANT-UHFFFAOYSA-N tfa trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.OC(=O)C(F)(F)F WROMPOXWARCANT-UHFFFAOYSA-N 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 125000000335 thiazolyl group Chemical group 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 229940116362 tragacanth Drugs 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 125000001834 xanthenyl group Chemical group C1=CC=CC=2OC3=CC=CC=C3C(C12)* 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Description
DERIVATIVES OF HYDROXAMIC ACID AS METALLOPROTEINASE INHIBITORS
The present invention relates to therapeutically active hydroxamic acid derivatives, to processes for their preparation, to pharmaceutical compositions containing them, and to the use of such compounds in medicine. In particular, the compounds are inhibitors of matrix metalloproteinases.
The matrix metalloproteinases (MMP's) are a family of zinc containing endopeptidases which are capable of cleaving large biomolecules such as the collagens, proteoglycans and gelatins. Imbalance between active MMPs and endogenous inhibitors, leads to excessive tissue disruption. The three main groups of MMPs are the collagenases, the gelatinases, and the stromelysins.
Collagenases include fibroblast collagenase (MMP-1), neutrophil collagenase (MMP-8), and collagenase 3 (MMP-13). Gelatinases include 72 kDa gelatinase (gelatinase A; MMP-2) and 92 kDa gelatinase (gelatinase B; MMP- 9). Stromelysins include stromelysin 1 (MMP-3), stromelysin 2 (MMP-10) and matrilysin (MMP-7). However there are MMPs which do not fit neatly into the above groups, for example metalloelastase (MMP-12), membrane-type MMP (MT-MMP or MMP-14) and stromelysin 3 (MMP-11).
Over-expression and activation of MMPs have been linked with a wide range of diseases such as cancer; rheumatoid arthritis; osteoarthritis; chronic inflammatory disorders, such as asthma, bronchitis and emphysema; cardiovascular disorders, such as atherosclerosis; comeal uiceration; dental diseases such as gingivitis and periodontal disease; neurological disorders, such as multiple sclerosis and restenosis. For example, MMP-12 is required for the development of cigarette smoke-induced emphysema in mice,
Science, 277, 2002 (1997). Inhibition of MMPs is therefore a strategy for treatment of such disease states. However, there is evidence that non- selective inhibition of matrix metalloproteinase activity may affect normal physiological process leading to dose limiting side effects. Selective inhibition of MMP-12 and/or MMP-9 is thought to be a particularly relevant strategy for intervention in inflammatory conditions.
Some MMPs can hydrolyse the membrane-bound precursor of the pro- inflammatory cytokine tumour necrosis factor a (TNF-a). This cleavage yields mature soluble TNF-a. and some inhibitors of MMPs can block production of
TNF-a both in vitro and in vivo. This pharmacological action is a probable contributor to the anti-inflammatory action of this class of compounds.
For a recent review of MMP inhibition as reflected in the patent literature, see
Doherty et. al. Therapeutic Developments in Matrix Metalloproteinase
Inhibition; Expert Opinions on Therapeutic Patents, 2002, 12, 665-707.
Very many of the MMP inhibitors of the prior art have a hydroxamic acid metal binding group (-CONHOH).
The present invention provides a class of compounds which in general are selective inhibitors of MMP-12 relative to the collagenases and stromelysins.
In addition, compounds of the invention can exhibit selective activity towards
MMP-9. Compounds of the invention are therefore indicated for treatment of diseases primarily mediated by MMP-12 and/or MMP-9, especially inflammatory conditions such as multiple sclerosis and fibrosis.
According to the invention, there is provided a compound of formula (l),or an enantiomer or diastereocisomer thereof, or a salt, hydrate or solvate thereof: 0
Ar-(Alk)
NR,R,
RO CONHOH
0) wherein
Ar represents an optionally substituted aryl, heteroaryl, Cz-Cs cycloalkyl or heterocycloakyl group;
R represents hydrogen or C+-Cs alkyl, or C3-C¢ cycloalkyl;
Alk represents a divalent C4-Cs alkylene or C»-Cs alkenylene radical; and
Ry and R; taken together with the nitrogen atom to which they are attached form a first heterocycloalkyl ring which is optionally fused to a second C3-Csg cycloalkyl or heterocycloalkyl! ring, the said first and second rings being optionally substituted by a at least one group of formula (ll):
SHAK), (X)-Ak—Z (I) wherein m, p and n are independently O or 1;
Z represents, hydrogen, or an optionally substituted carbocyclic or heterocyclic ring of from 5 to 7 ring atoms which is optionally fused to another optionally substituted carbocyclic or heterocyclic ring of from 5 to 7 ring atoms;
Alk' and Ali? independently represent optionally substituted divalent C4-C3 alkylene radicals;
X represents -O-, -S-, -S(0)-, -S(0z)-, -C(=0)-, -NH-, -NRa-, -S(O2)NH-, -S(O2)NR3-, -NHS(Oz)-, or -NR3S(02)-, where Rj is C4-C; alkyl.
As used herein the term “(C,-Cp)alkyl“ where a and b are integers refers to a straight or branched chain alkyl moiety having from a to b carbon atoms, including for example, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec- butyl , n-pentyl and n-hexyl, depending on the values of a and b.
As used herein the term "divalent (C,-Cp)alkylene radical" where a and b are integers refers to a saturated hydrocarbon chain having from a to b carbon atoms and two unsatisfied valences.
As used herein the term “(Ca-Cp)alkenyl“ where a and b are integers refers to a straight or branched chain alkenyl moiety having from a to b carbon atoms having at least one double bond of either E or Z stereochemistry where applicable. The term includes, for example, vinyl, allyl, 1- and 2-butenyl and 2- methyl-2-propenyl, depending on the values of a and b.
As used herein the term "divalent (C4-Cp)alkenylene radical refers to a hydrocarbon chain having from a to b carbon atoms, at least one double bond, and two unsatisfied valences.
As used herein the unqualified term "carbocyclyl” or “carbocyclic” refers to a ring or ring system of from 3 to 14 ring atoms which are all carbon, and includes “aryl”, “cycloalkyl”, and “cycloalkenyl” as defined below.
As used herein the unqualified term "cycloalkyl refers to a saturated alicyclic moiety having from 3-8 carbon atoms consisting of a single ring (e.g. cyclohexyl) or multiple condensed rings (e.g.norbornyl). Preferred cycloalkyl include cyclopentyl, cyclohexyl, norbomyl and the like.
As used herein the unqualified term "cycloalkenyl® refers to an unsaturated alicyclic moiety having from 3-8 carbon atoms and includes, for example, cyclopropenyl, cyclobutenyl, cyclopentenyl, cyclohexenyl, cycloheptenyl and cyclooctenyl. In the case of cycloalkenyl rings of from 5-8 carbon atoms, the ring may contain more than one double bond.
As used herein the unqualified term "aryl® refers to an aromatic carbocyclic group of from 6 to 14 carbon atoms having a single ring or multiple condensed rings and to two covalently linked monocyclic carbocyclic aromatic groups.
Examples of aryl include phenyl, biphenyl and the like.
As used herein the unqualified term "heterocyclyl or “heterocyclic” refers to a ring or ring system whose ring members include one or more hetero atoms selected from O, S, and N, and the term includes “heteroaryl” and “heterocycloalkyl” as defined below.
As used herein, the unqualified term “heterocycloalkyl” refers to a cycloaklyl group as defined above, in which up to 3 ring carbon atoms are replaced by heteroatoms selected from O, S and N. Preferred heterocycloalkyl include pyrrolidine, piperidine, piperazine, 1-methyl piperazine, morpholine, and the like.
As used herein the unqualified term "heteroaryl" refers to a monocyclic, or fused bicyclic or tricyclic aromatic ring or ring system containing one or more heteroatoms selected from O, S and N, and to groups consisting of two covalently linked monocyclic aromatic rings containing one or more such heteroatoms; and to groups consisting of a monocyclic carbocyclic aromatic group covalently linked to monocyclic aromatic ring containing one or more heteroatoms. Particular examples of heteroaromatic groups include optionally substituted pyridyl, pyrimidinyl, pyrrolyl, furyl, thienyl, thiophenyl, imidazolyl, oxazolyl, thiazolyl, isothiazolyl, pyrazolyl, 1,2,3-triazolyl, 1,2,4-triazolyl, 1,2,3- oxadiazolyl, 1,2,4-oxadiazolyl, 1,2,5-oxadiazolyl, 1,3,4-oxadiazolyl, 1,2,4- triazinyl, 1,2,3-triazinyl, benzofuryl, [2,3-dihydro}benzofuryl, isobenzofuryl, benzothienyl, benzotriazolyl, isobenzothienyl, indolyl, isoindolyl, 3H-indolyl, benzimidazolyl, imidazo[1,2,-c]pyridyl, benzothiazolyl, benzoxazolyl, quinazolyl, quinazolinyl, phthalazinyl, quinoxalinyl, cinnolyl, naphthyridinyl, pyrido[3,4-c]pyridyl, pyrido[3,2-c]pyridyl, pyrido{3,4,3-C]pyridyl, quinolyl, isoquinolyl, tetrazolyl, 5,6,7,8-tetrahydroquinolyl, 5,6,7,8-tetrahydroisoquinolyl, purinyl, pteridinyl, carbazolyl, xanthenyl or benzoquinolyl.
Unless otherwise specified in the context in which it occurs, the term "substituted as applied to any moiety herein means substituted, for example, with at least one substituent selected from (C1-Cg)alkyl, (C1-Cg)alkoxy, hydroxy, hydroxy(C4-Cg)alkyl, mercapto, mercapto(C1-Ce)alkyl, (C+-
Ce)alkylthio, halo (including fluoro and chloro), trifluoromethyl, trifluoromethoxy, nitro, nitrile (-CN), oxo, phenyl, -COOH, -COOR*, -COR*, -SO,R*, -CONH;, -SO,NH,, -CONHR", -SO,NHR*, -CONR*R®, -SO.NR*R®, -NHz, -NHR*, -NR"RE, -OCONH,, -OCONHR* ,-OCONR*R®, -NHCOR?, -NHCOOR?", -NRBCOORA, -NHSO.0R?, -NR®SO,0R", -NHCONH,,
-NRACONH,, -NHCONHR® -NR*CONHRE, -NHCONR*R® or -NRACONR*R®? wherein R* and R® are independently a (C;-Cg)alkyl or phenyl group.
As used herein the term “salt” includes base addition, acid addition and quaternary salts. Compounds of the invention which are acidic can form salts, including pharmaceutically acceptable salts, with bases such as alkali metal hydroxides, e.g. sodium and potassium hydroxides; alkaline earth metal hydroxides e.g. calcium, barium and magnesium hydroxides; with organic bases e.g. N-methyl-D-glucamine, choline tris(hydroxymethyl)amino-methane,
L-arginine, L-lysine, N-ethyl piperidine, dibenzylamine and the like. Those compounds (1) which are basic can form salts, including pharmaceutically acceptable salts with inorganic acids, e.g. with hydrohalic acids such as hydrochloric or hydrobromic acids, sulphuric acid, nitric acid or phosphoric acid and the like, and with organic acids e.g. with acetic, tartaric, succinic, fumaric, maleic, malic, salicylic, citric, methanesulphonic, p-toluenesulphonic, benzoic, benzenesunfonic, glutamic, lactic, and mandelic acids and the like.
For a review on suitable salts, see Handbook of Pharmaceutical Salts:
Properties, Selection, and Use by Stahl and Wermuth (Wiley-VCH, Weinheim,
Germany, 2002).
The term ‘solvate’ is used herein to describe a molecular complex comprising the compound of the invention and a stoichiometric amount of one or more pharmaceutically acceptable solvent molecules, for example, ethanol. The term ‘hydrate’ is employed when said solvent is water.
Compounds with which the invention is concemed which may exist in one or more stereocisomeric form, because of the presence of asymmetric atoms or rotational restrictions, can exist as a number of stereoisomers with R or S stereochemistry at each chiral centre or as atropisomeres with R or S stereochemistry at each chiral axis. The invention includes all such enantiomers and diastereoisomers and mixtures thereof. In particular the invention includes compounds having the stereochemical configuration (IA):
O
Ar-(Alk)
RO CONHOH
(1A)
The compounds of the invention include compounds of formula (I) as hereinbefore defined, including all polymorphs and crystal habits thereof, prodrugs and isomers thereof (including optical, geometric and tautomeric isomers) as hereinafter defined and isotopically-labeled compounds of formula (0).
The group Ar
Ar may be, for example, a 5- or 6- membered monocyclic ary! or heteroaryl ring, which is optionally substituted, for example in the 4- position in the case of a 6-membered ring, or in the 2- and/or 3- position in the case of a 5- membered ring, by at least one substituent selected from (C;-Cs)alkyl, (C-
Ca)alkoxy, hydroxy, hydroxy(C+-Cs)alkyl, mercapto, mercapto(C4-Cs)alkyl, (C4-
Cs)alkyithio, halo, trifluoromethyl, trifluoromethoxy, nitro, nitrile (-CN), -COOH, -COOR*, -COR? -SO;R", -CONHz, -SO-NH,, -CONHR*, -SO.NHR", -CONR*R®, -SO;NR"R®, -NH,, -NHR", -NR"RE, -OCONH,, -OCONHR" -OCONR*R®, -NHCOR", -NHCOOR*, -NRECOOR", -NHSO,OR", -NRBSO.0R", -NHCONH,, -NRACONH,, -NHCONHR® -NRACONHR®, -NHCONRAR®, or -NR*CONR"RE wherein R* and R® are independently C,-C; alkyl, phenyl or a 5- or 6-membered monocyclic aryl or heteroaryl ring.
Ar may be, for example phenyl, 2-, 3-, or 4-pyridyl, 2-, or 3-thienyl, or 2-, or 3- furanyl, optionally substituted as specified above in relation to formula (I).
Preferably the substituent can be, for example, methoxy, ethoxy, trifluoromethoxy, methyl, ethyl, trifluoromethyl, hydroxyl, mercapto, fiuoro, chloro, or bromo. Presently it is preferred that Ar be 4-(C4-Csalkoxy)phenyl, and the most preferred being the ethoxyphenyl.
The group R
In one embodiment of the invention R is hydrogen.
In another embodiment of the invention R is (C4-Cg)alkyl, for example ethyl, n- propyl, isopropyl, n-, sec or tert-butyl. In a preferred embodiment, R is methyl.
In yet another embodiment R is C3-Ce cycloalkyl, for example cyclopropyl, or cyclopentyl.
The Alk radical
Alk may be, for example, -CHa-, -CH2CH.-, -CH,CH(CH3)-, -CH2CH,CH-, -CH,CH>CH,CH,-, -CH=CH-, -CH,CH=CH-, -CH,CH=CHCH,-, or -CH=CHCH=CH-. Presently it is preferred that Alk be -CH,CH,CHo-.
The group -NR;R.
This group is a saturated heterocyclic first ring of 5 to 7 atoms which is optionally fused to a saturated or unsaturated carbocyclic or heterocyclic second ring of 5 to 7 atoms. (The said first and/or second ring may optionally be substituted by a group of formula (ll), discussed below). One of the heteroatoms of the group -NR+R: is of course the nitrogen shown, and it may be the sole heteroatom in the ring system of there may be other nitrogen, oxygen or sulphur ring atoms.
The group -NR1R2 may be unsubstituted or substituted by at least one group (mn: —HAK),-X-AKTZ ()
It will be noted that since an optional substituent in either Alk' or Alk® may be oxo, a carbonyl group may be located adjacent the X element, forming for example combinations such as amide, reverse amide and carboxy linkages.
In one embodiment of the invention, R; and R; taken together with the nitrogen atom to which they are attached form a morpholyl group, optionally substituted by at least one group of formula (li).
In another embodiment of the invention, Ry and R; taken together with the nitrogen atom to which they are attached form a thiomorpholyl group, optionally substituted by at least one group of formula (Il).
In another embodiment of the invention, Ry and R; taken together with the nitrogen atom to which they are attached form a piperidinyl group, optionally substituted by at least one group of formula (l1).
In another embodiment of the invention, Ry and R; taken together with the nitrogen atom to which they are attached form a pyrrolidinyl group, optionally substituted by at least one group of formula (lI).
In another embodiment of the invention, Ry and R: taken together with the nitrogen atom to which they are attached form a piperazinyl group, optionally substituted by at least one group of formula (Hi).
In one particular embodiment of the invention, group (ll) is such thatp is 0, Z is hydrogen and at least one of n and m is 1. In this subclass the group (Il) is optionally substituted C,-Cs alkyl, which may be linked to a ring carbon or to a ring nitrogen of the -NR;R. group. For example when -NR;R; is piperidinyl or piperazinyl, the 4-C (in the former) and the 4-N (in the latter) may be substituted by methyl, ethyl, or n- or iso-propyl.
In a second particular embodiment of the invention, group (ll) is such that m, n and p are all 0 and Z is a carbocyclic or heterocyclic ring directly linked to a ring carbon or ring nitrogen of the -NR1R2 group. Examples of such directly linked rings Z include cyclopentyl and cyclohexyl, and (preferably) aryl or heteroaryl! rings such as phenyl, pyridyl, thienyl, furanyl, and pyrimidinyl.
These directly linked rings may themselves be substituted by optional substituents, for example methoxy, ethoxy, n- or iso-propoxy, trifluoromethoxy, methylenedioxy, ethylenedioxy, methyl, ethyl, n- or isopropyi, trifluoromethyl, fluoro, chloro, bromo, methylsutfonyl, phenylsulfonyl, or mono- or di-(C4-Cs)alkylamino.
In a third particular embodiment of the invention, group (Il) is such that p is 0, at least one of mand nis 1, and Z is a carbocyclic or heterocyclic ring linked to a ring carbon or ring nitrogen of the -NR¢R group via a C4-Cg alkylene linker between Z and the -NR+Rz ring. In this case, the ring Z may be any of those optionally substituted Z rings discussed and preferred above in the case of the second subclass of groups (11), but here Z is linked to the -NR;R; ring via an optionally substituted C-Cg alkylene linker radical, such as a ~CHa- or ~CH,CHy- radical.
In a fourth particular embodiment of the invention, group (il) is such that p is 1, so that the group (ll) contains the X heteroatom. Clearly when mis 0, X is directly linked to the -NR:R. ring; when m and n are both 1 X interrupts a Cs-
Ce alkylene linker between Z and the -NR:Rz ring; and when one of m and n is 1 and the other 0, the group (ll) represents a variety of O, S- or N containing substituents either directly linked to the -NR;R: ring, or linked via a C,-
Csalkylene linker.
A particular embodiment of the invention comprises compounds of formula (IB) or (IC) and salts, hydrates and solvates thereof, especially compounds having the stereoconfiguration shown in formula (IA above):
R, r 0 0
N N
R, RO CONHOH R; RO CONHOH (IB) (IC) wherein R is hydrogen or methyl, Rs is trifluoromethyl, trifluoromethoxy C-
Caalkoxy, hydroxy, or halo; Ry is (i) -SO2Rs or -CORs wherein Rs is C1-Cgalky!
or phenyl or monocyclic heteroaryl having 5 or 6 ring atoms, optionally substituted by (C4-Ca)alkyl, (C1-Cs)alkoxy, hydroxy, hydroxy(C1-Cz)alkyl, mercapto, mercapto(C+-Ca)alkyl, (C4-Cs)alkylthio, halo, trifluoromethyl, trifluoromethoxy or (ii) phenyl or monocyclic heteroaryl having 5 or 6 ring atoms; optionally substituted by (C-Cs)alkyl, (C4-Ca)alkoxy, hydroxy, hydroxy(C,-Cs)alkyl, mercapto, mercapto(C+-Cs)alkyl, (C1-Cs)alkylthio, halo, trifluoromethyl, trifluoromethoxy). Examples of heteroaryl rings forming part of
Ra4 in this embodiment include pyridyl, pyrimidinyl, triazinyl, thienyl, and furanyl.
Specific embodiments of the invention are compounds selected from the group consisting of the following: 6-(4-ethoxy-phenyl)-2S-hydroxy-3R-(pyrrolidine-1-carbonyl)-hexanoic acid hydroxyamide. 3R-(6,7-dimethoxy-3,4-dihydro-1H-isoquinoline-2-carbonyl)-6-(4-ethoxy- phenyl)-2S-hydroxy-hexanoic acid hydroxyamide. 6-(4-ethoxy-phenyl)-2S-hydroxy-3R-[4-(3-methoxy-phenyl)-piperazine-1- carbonyl]-hexanoic acid hydroxyamide. 6-(4-ethoxy-phenyl)-2S-hydroxy-3R-[4-(4-methoxy-phenyl)-piperazine-1- carbonyl]-hexanoic acid hydroxyamide. 6-(4-ethoxy-phenyl)-2S-hydroxy-3R-(4-pyridin-2-yl-piperazine-1-carbonyl)- hexanoic acid hydroxyamide. 6-(4-ethoxy-phenyl)-2S-hydroxy-3R-(4-pyridin-4-yi-piperazine-1-carbonyl)- hexanoic acid hydroxyamide. 6-(4-ethoxy-phenyl)-2S-hydroxy-3R-(morpholine-4-carbonyl)-hexanoic acid hydroxyamide.
6-(4-ethoxy-phenyl)-2S-hydroxy-3R-(2RS-methyl-morpholine-4-carbonyi)- hexanoic acid hydroxyamide. 6-(4-ethoxy-phenyl)-2S-hydroxy-3R-(2,6-RS-dimethyl-morpholine-4-carbonyl)- hexanoic acid hydroxyamide. 6-(4-ethoxy-phenyl)-2S-hydroxy-3R-(thiomorpholine-4-carbonyl)-hexanoic acid hydroxyamide. 3R-(4-benzy!-piperidine-1-carbonyl)-6-(4-ethoxy-phenyl)-2S-hydroxy-hexanoic acid hydroxyamide. 3R-(4-benzo[1,3]dioxol-5-yimethyl-piperazine-1-carbonyl)-6-(4-ethoxy-phenyl)- 2S-hydroxy-hexanoic acid hydroxyamide. 6-(4-ethoxy-phenyl)-2S-hydroxy-3R-(4-pyridin-4-ylmethyl-piperazine-1- carbonyl)-hexanoic acid hydroxyamide. 6-(4-ethoxy-phenyl)-2S-hydroxy-3R-(4-benzylpiperazine-1-carbonyl)-hexanoic acid hydroxyamide. 6-(4-ethoxy-phenyl)-2S-hydroxy-3R-(4-pyrimidin-2-yl-piperazine-1-carbonyl)- hexanoic acid hydroxyamide. 6-(4-ethoxy-phenyl)-2S-hydroxy-3R-[4-(4-trifluoromethyi-pyrimidin-2-yl)- piperazine-1-carbonyl]-hexanoic acid hydroxyamide. 6-(4-ethoxy-phenyl)-2S-hydroxy-3R-[4-(4-chloro-pyrimidin-2-yl)-piperazine-1- carbonyl]-hexanoic acid hydroxyamide.
3R-[4-(4,6-dimethoxy-[1,3,5triazin-2-yl)-piperazine-1-carbonyl}-6-(4-ethoxy- phenyl)-2S-hydroxy-hexanoic acid hydroxyamide.
6-(4-ethoxy-phenyl)-2S-hydroxy-3R-[4-(3-trifluoromethyl-phenyl)-piperazine-1- carbonyl]-hexanoic acid hydroxyamide. 6-(4-ethoxy-phenyl)-2S-hydroxy-3R-[4-(2-fluoro-phenyl)-piperazine-1- carbonyl]-hexanoic acid hydroxyamide. 3R-[4-(acetyl-methyl-amino)-piperidine-1-carbonyl]-6-(4-ethoxy-phenyl)-2S- hydroxy-hexanoic acid hydroxyamide. 6-(4-ethoxy-phenyl)-2S-hydroxy-3R-{4-(methyl-propyl-amino)-piperidine-1- carbonyl]-hexanoic acid hydroxyamide. 6-(4-ethoxy-phenyi)-2S-hydroxy-3R-(3S-benzyl-morpholine-4-carbonyl)- hexanoic acid hydroxyamide. 6-(4-ethoxy-phenyl)-2S-hydroxy-3R-(3S-isobutyl-morpholine-4-carbonyi)- hexanoic acid hydroxyamide. 6-(4-ethoxy-phenyl)-2S-hydroxy-3R-(3S-phenyl-morpholine-4-carbonyl)- hexanoic acid hydroxyamide. 3R-(4-benzyl-3RS-methyl-piperazine-1-carbonyi)-6-(4-ethoxy-phenyl)-2S- hydroxy-hexanoic acid hydroxyamide. 3R-(3S,4-dibenzyl-piperazine-1-carbonyl)-6-(4-ethoxy-phenyl)-2S-hydroxy- hexanoic acid hydroxyamide. 3R-(4-benzyl-3RS-phenyl-piperazine-1-carbonyl)-6-(4-ethoxy-phenyl)-2S- hydroxy-hexanoic acid hydroxyamide. 4-(4-benzo[1,3]dioxol-5-yimethyl-piperazin-1-yi)-2S,N-dihydroxy-4-oxo-3R-(4- trifluoromethoxy-benzyl)-butyramide. 3R-benzyl-28,N-dihydroxy-4-morpholin-4-yl-4-oxo-butyramide.
3R-(4-Benzyloxy-benzy!)-2S,N-dihydroxy-4-oxo-4-piperidin-1-yl-butyramide. 2S,N-dihydroxy-3R-(4-hydroxy-benzyl)-4-oxo-4-piperidin-1-yl-butyramide. 4-(4-benzo[1,3]dioxol-5-ylmethyl-piperazin-1-yl)-3R-(4-benzyloxy-benzyl)- 2S,N-dihydroxy-4-oxo-butyramide. 6-(3,5-bis-trifluoromethyl-phenyl)-2S-hydroxy-3R-(morpholine-4-carbonyl)- hexanoic acid hydroxyamide. 3R-(4-benzyl-piperidine-1-carbonyl)-6-(3,5-bis-trifluoromethyl-phenyi)-2S- hydroxy-hexanoic acid hydroxyamide. 6-(3,5-bis-trifluoromethyl-phenyl)-2S-hydroxy-3R-(4-pyridin-2-yl-piperazine-1- carbonyl)-hexanoic acid hydroxyamide. 6-(3,5-bis-trifluoromethyl-phenyl)-3R-(6,7-dimethoxy-3,4-dihydro-1H- isoquinoline-2-carbonyl)-2S-hydroxy-hexanoic acid hydroxyamide. 6-(3,5-bis-trifluoromethyl-phenyl)-2S-hydroxy-3R-(pyrrolidine-1-carbonyl)- hexanoic acid hydroxyamide 3R-(2S-benzyl-4-methyl-piperazine-1-carbonyl)-6-(4-ethoxy-phenyl)-2S-
hydroxy-hexanoic acid hydroxyamide. 6-(4-ethoxy-phenyl)-2S-hydroxy-3R-[4-(4-trifluoromethoxy-benzenesulfonyl)- piperazine-1-carbonyi]-hexanoic acid hydroxyamide. 6-(4-ethoxy-phenyl)-2S-hydroxy-3R-[4-(toluene-4-sulfonyl)-piperazine-1- carbonyl}-hexanoic acid hydroxyamide. 3R-{4-(5-bromo-thiophene-2-sulfonyl)-piperazine-1-carbonyl]-6-(4-ethoxy- phenyl)-2S-hydroxy-hexanoic acid hydroxyamide.
3R-[4-(5-benzenesulfonyl-thiophene-2-sulfonyl)-piperazine-1-carbonyl]-6-(4- ethoxy-phenyl)-2S-hydroxy-hexanoic acid hydroxyamide. 3R-[4-(4-butoxy-benzenesulfonyl)-piperazine-1-carbonyl]-6-(4-ethoxy-phenyl)- 2S-hydroxy-hexanoic acid hydroxyamide. 6-(4-ethoxy-phenyl)-2S-hydroxy-3R-[4-(4-methoxy-2,3,6-trimethyl- benzenesulfonyl)-piperazine-1-carbonyl}-hexanoic acid hydroxyamide. 3R-[4-(3,4-dimethoxy-benzenesulfonyl)-piperazine- 1-carbonyl}-6-(4-ethoxy- phenyl)-2S-hydroxy-hexanoic acid hydroxyamide. 6-(4-methoxy-phenyl)-2S-hydroxy-3R-[{4-(2-fluoro-phenyl)-piperazine-1- carbonyl}-hexanoic acid hydroxyamide. 6-(4-methoxy-phenyl)-2S-hydroxy-3R-(4-pyridin-2-yl-piperazine-1-carbonyl)- hexanoic acid hydroxyamide. 6-(4-fluoro-phenyl)-3R-[4-(2-fluoro-phenyl)-piperazine-1-carbonyli]-2S-hydroxy- hexanoic acid hydroxyamide. 6-(4-fluoro-phenyl)-2S-hydroxy-3R-(4-pyridin-2-yl-piperazine-1-carbonyl)- hexanoic acid hydroxyamide. 3R-(4-benzyl-2S-methyl-piperazine-1-carbonyl)-6-(4-ethoxy-phenyl)-2S- hydroxy-hexanoic acid hydroxyamide. 3R-(4-benzyl-2S-methyl-piperazine-1-carbonyl)-6-(4-methoxy-phenyl)-2S- hydroxy-hexanoic acid hydroxyamide. 3R-(4-benzyl-2S-i-butyl-piperazine-1-carbonyl)-6-(4-methoxy-phenyl)-2S- hydroxy-hexanoic acid hydroxyamide.
3R-~(4-benzyl-2S-methyl-piperazine-1-carbonyl)-6-(4-fluoro-phenyi)-2S- hydroxy-hexanoic acid hydroxyamide. 3R-(4-benzyl-2S-i-butyl-piperazine-1-carbonyl)-6-(4-fluoro-phenyl)-2S- hydroxy-hexanoic acid hydroxyamide. 4-[5-(4-ethoxy-phenyl)-2R-(1S-hydroxy-hydroxycarbamoyl-methyi)-pentanoyl)- 2S-methyl-piperazine-1-carboxylic acid tert-butyl ester. 4-[5-(4-ethoxy-pheny!)-2R-(1S-hydroxy-hydroxycarbamoyl-methyl)-pentanoyi)- 28-i-butyl-piperazine-1-carboxylic acid tert-butyl ester. 4-[5-(4-methoxy-phenyl)-2R-(1S-hydroxy-hydroxycarbamoyl-methyl)- pentanoyl]-2S-methyl-piperazine-1-carboxylic acid tert-butyl ester. 4-[5-(4-methoxy-phenyl)-2R-(1S-hydroxy-hydroxycarbamoyl-methyl)- pentanoyi]-2S-i-butyl-piperazine-1-carboxylic acid tert-butyl ester. 4-[5-(4-fluoro-phenyl)-2R-(1S-hydroxy-hydroxycarbamoyl-methyl)-pentanoyl]- 2S-methyl-piperazine-1-carboxylic acid tert-butyl ester. 4-[5-(4-fluoro-phenyl)-2R-(1S-hydroxy-hydroxycarbamoyl-methyi)-pentanoyi}- 2S-i-butyl-piperazine-1-carboxylic acid tert-butyl ester. 6-(4-ethoxy-phenyl)-2S-methoxy-3R-[4-(2-fluoro-phenyl)-piperazine-1- carbonyl]-hexanoic acid hydroxyamide.
As mentioned above, the present compounds are useful in human or veterinary medicine since they are active as inhibitors of MMPs, in particular as selective inhibitors of MMP-12 (and/or MMP-9) relative to MMP-1 and other collagenases and stromelysins. Accordingly in another aspect, this invention concems:
(i) a method of management (by which is meant treatment or prophylaxis) of diseases or conditions responsive to inhibition of MMP-12 and/or MMP-9 in mammals, in particular in humans, which method comprises administering to the mammal an effective amount of a compound of formula (1) defined above, or a pharmaceutically acceptable salt thereof; and (ii) a compound of formula (1) defined above, for use in human or veterinary medicine, particularly in the management (by which is meant treatment or prophylaxis) of diseases or conditions responsive to inhibition of MMP-12 and/or MMP-9. (Diseases or conditions responsive to inhibition of MMP-12 and/or MMP-9 include bone resorption, tumour growth or invasion by secondary metastases; rheumatoid arthritis, septic arthritis, osteoarthritis, periodontitis, gingivitis, corneal ulceration, cardiac hypertrophy, acute respiratory distress syndrome, neuroinflammatory disorders, e.g. multiple sclerosis; restenosis; emphysemia; fibrotic didease e.g. fibrosis post radiotherapy, kerotid scarring, liver fibrosis and cystic fibrosis; chronic obstructive pulmonary disease; bronchitis; asthma; autoimmune disease; transplant rejection (e.g. graft versus host disease); cystic fibrosis; psoriasis; psoriatic arthritis; degenerative cartilage loss; inflammatory gastric conditions, e.g.
Crohn's disease, inflammatory bowel disease, and ulcerative colitis; atopic dermatitis, epidermolysis bullosa; epidermic ulceration; a neuropathy or nephropathy e.g.interstitial nephritis, glomerulonephriris or renal failure; ocular inflammation; liver cirrhosis, Sjoegren’s syndrome; or an inflammatory condition of the nervous system.); and
(iii) a compound of formula (1) for use as a medicament; and
(iv) the use of a compound of formula (I) defined above in the preparation of an agent for the management (by which is meant treatment or prophylaxis) of diseases or conditions responsive to inhibition of MMP-12 and/or MMP-9; and (v) the use of a compound of formula (I) for the preparation of a medicament for the prevention or treatment of a disease selected from inflammatory diseases including multiple sclerosis, emphysemia, bronchitis, asthma, and a disease related to MMP-12 and/or MMP-9.
In a further aspect of the invention there is provided a pharmaceutical or veterinary composition comprising a compound of formula (1) defined above together with a pharmaceutically or veterinarily acceptable excipient or carrier.
It will be understood that the specific dose level for any particular patient will depend upon a variety of factors including the activity of the specific compound employed, the age, body weight, general health, sex, diet, time of administration, route of administration, rate of excretion, drug combination and the severity of the particular disease undergoing therapy. Optimum dose levels and frequency of dosing will be determined by clinical trial.
The compounds with which the invention is concerned may be prepared for administration by any route consistent with their pharmacokinetic properties.
The orally administrable compositions may be in the form of tablets, capsules, powders, granules, lozenges, liquid or gel preparations, such as oral, topical, or sterile parenteral solutions or suspensions. Tablets and capsules for oral administration may be in unit dose presentation form, and may contain conventional excipients such as binding agents, for example syrup, acacia, gelatin, sorbitol, tragacanth, or polyvinyl-pyrrolidone; fillers for example lactose, sugar, maize-starch, calcium phosphate, sorbitol or glycine; tabletting lubricant, for example magnesium stearate, talc, polyethylene glycol or silica; disintegrants for example potato starch, or acceptable wetting agents such as sodium lauryl sulphate. The tablets may be coated according to methods well known in normal pharmaceutical practice. Oral liquid preparations may be in the form of, for example, aqueous or oily suspensions, solutions, emulsions, syrups or elixirs, or may be presented as a dry product for reconstitution with water or other suitable vehicle before use. Such liquid preparations may contain conventional additives such as suspending agents, for example sorbitol, syrup, methyl cellulose, glucose syrup, gelatin hydrogenated edible fats; emulsifying agents, for example lecithin, sorbitan monooleats, or acacia;
non-aqueous vehicles (which may include edible oils), for example almond oil, fractionated coconut oil, oily esters such as glycerine, propylene glycol, or ethyl alcohol; preservatives, for example methyl or propyl p-hydroxybenzoate or sorbic acid, and if desired conventional flavouring or colouring agents.
For topical application to the skin, the drug may be made up into a cream, lotion or ointment. Cream or ointment formulations which may be used for the drug are conventional formulations well known in the art, for example as described in standard textbooks of pharmaceutics such as the British
Pharmacopoeia.
For topical application to the eye, the drug may be made up into a solution or suspension in a suitable sterile aqueous or non aqueous vehicle. Additives, for instance buffers such as sodium metabisulphite or disodium edeate; preservatives including bactericidal and fungicidal agents such as phenyl mercuric acetate or nitrate, benzalkonium chloride or chlorhexidine, and thickening agents such as hypromellose may also be included.
The active ingredient may also be administered parenterally in a sterile medium. Depending on the vehicle and concentration used, the drug can either be suspended or dissolved in the vehicle. Advantageously, adjuvants such as a local anaesthetic, preservative and buffering agents can be dissolved in the vehicle.
Compounds of formula (I) may be prepared by standard literature methods, as illustrated in the Examples herein. In general, the compounds wherein R is hydrogen may be prepared by coupling a dioxolane-protected di-carboxylic acid of formula (Ill) with the desired cyclic amine HNRRz:
Ar-(Alk) COOH 1 (11)
wherein Ry, Ra: Ar and Alk are as defined in relation to formula (1), to form the intermediate (IIIA) oO
Ar-(Alk)
NR,R, 0) (INA) i then reacting intermediate (lllA) with hydroxylamine.
Methods of coupling amines with carboxylic acids to form amides are very well known, for example from the art of peptide synthesis.
Thus, the invention also includes (vj a compound of formula (IIIB) wherein Ry, Rz, Ar and Alk are as defined in relation to formula (1) (vii) a process for the preparation of a compound of formuia (I) defined above, comprising the deprotection and/or transformation of a compound of formula (il1A) as defined above, ) wherein Rs, Ra, Ar and Alk are as defined in relation to formula (1) (viii) a process for the preparation of a compound of formula (IlIA) comprising the step of reacting a compound of formula (ll) with a cyclic amine
HNR;R.., wherein Ry, Ra: Ar and Alk are as defined in relation to formula (1),
The following preparative Examples describe the preparation of compounds useful in accordance with the invention
The following abbreviations have been used in the examples:
AcOEt - Ethyl acetate
CH3CN - Acetonitrile
DMF - N,N-Dimethylformamide
HOBT - 1-Hydroxybenzotriazole
HOAT - 1-Hydroxyazobenzotriazole
MgSO, — Magnesium sulfate
Pfp — Pentafluorophenol
WSCDI - N-(3-Dimethylaminopropy!)-N'-ethylcarbodiimide hydrochloride
HCI - Hydrochloric acid
P(O-Tol)s — Tri-O-tolylphosphine
THF — Tetrahydrofuran
TFA — Trifluoroacetic acid
Z - Benzyloxycarbonyl
Example 1: 6-(4-ethoxy-phenyl)-2S-hydroxy-3R-(pyrrolidine-1-carbonyl)- hexanoic acid hydroxyamide. 0 0
EtO HO o
HN
OH jal Step A he Gl Step B ox" Step C
HO” ~CO,iPr HO” ~CO,iPr EtO HO” ~Cco,iPr
EtO HO” ~CO,iPr Eto HO” ~COH ‘ F oF F
CoH
Step F 0 F step G
EtO Q 0 ~ 80 o F ’
Fe Fe 0 .
EtO o~ ——" EO HO lo) 4 HN
OH
Reagents and conditions. A: LIHMDS, AllBr, THF, -78C to RT; B: ArBr, P(o-Tol);, Pd(OAc),, NEt,;, CH,CN;
C: 10%Pd/C, H,, MeOH; D: LiOH, MeOH, H,0; E: CuCl,, dimethoxypropane, acetone; F: pentafiuorophenol,
WSCDI, HOAt, CH,CL,; G: pyrrolidine, NEty, CH,Cl,, H: , ,NH,OH, iPrOH
Scheme 1
Example 1 was prepared as outlined in Scheme 1 using procedures described below.
Step A: 2R-allyl-3S-hydroxy-succinic acid diisopropylester.
To a cold (-78C) solution of 2S-hydroxy-succinic acid diisopropyl ester (19.70 ml, 95 mmol) in THF (35 ml) was added LiHMDS (200 ml, 0.2 mol, 2.1 eq.)
dropwise. The reaction mixture was stirred at -78C for two hours and then at - 30C for 30 min. The reaction mixture was then cooled to -78C and ally! bromide (12.36 ml, 0.14 mol, 1.5 eq.) added dropwise. The reaction mixture was then allowed to warm to RT ovemight. It was poured into a saturated solution of NH4Cl/ice (200 ml). Extraction with AcOEt (3 X 200 ml) followed by a wash with water (50 ml) and with brine (50 ml) afforded a yellow oil after removal of the solvents under vacuo. Purification by flash chromatography gave 2R-allyl-3S-hydroxy-succinic acid diisopropylester as a colourless oil (7.76 g, de = 80%, 40% yield). "H-NMR; delta (CDCls): 5.77-5.88 (1H, m), 4.98-5.21 (4H, m), 4.22 (1H, brs), 3.18 (1H, brs), 2.87-2.94 (1H, m), 2.56-2.65 (1H, m), 2.40-2.48 (1H, m), 1.29 (6H, d, J=6.3 Hz), 1.22 (6H, d, J=6.3 Hz).
LRMS: +ve ion 281 (M+Na).
Step B: 2R-[3-(4-ethoxy-phenyl)-allyl}-3S-hydroxy-succinic acid diisopropyl ester.
To a solution of 2R-allyl-3S-hydroxy-succinic acid diisopropylester (4.79 g, 18.5 mmol), 4-bromo phenetole (3.19 mi, 22.2 mmol, 1.2 eq.) and NEt; (6.22 ml, 44.6 mmol, 2.4 eq.) in CHsCN (40 ml), was added a sonicated (for 2 min) suspension of P(O-Tol)s (0.57 g, 2.22 mmol, 0.1 eq.) and Pd(OAc). (209 mg, 5%) in CH3CN (5 ml). The reaction mixture was heated to reflux for 2 hrs.
CH3CN was removed under vacuo. The crude was extracted with AcOEt (3 X 200 ml), washed with water (50 ml) and with brine (50 ml). A purification by flash chromatography afforded the desired 2R-[3-(4-ethoxy-phenyl)-allyl]-3S- hydroxy-succinic acid diisopropyl ester (5.92 g, 84% yield). "H-NMR; delta (CDCls): 7.28 (2H, d, J=8.8 Hz), 6.83 (2H, d, J=8.8), 6.46 (1H, d, J=15.7 Hz), 6.02-6.12 (1H, m), 4.98-5.13 (2H, m), 4.26 (1H, dd, J=7.1, 3.0
Hz), 4.02 (2H, q, J=7.0 Hz): 3.23 (1H, d, J=7.1 Hz), 2.92-2.97 (1H, m), 2.68- 2.79 (1H, m), 2.49-2.62 (1H, m), 1.41 (3H, t, J=7.0 Hz), 1.19-1.30 (12H, m).
LRMS: +ve ion 401 (M+Na).
Step C: 2R-[3-(4-ethoxy-phenyl)-propyl}-3S-hydroxy-succinic acid diisopropyl ester.
To a solution of 2R-[3-(4-ethoxy-phenyl)-allyl]-3S-hydroxy-succinic acid diisopropyl ester (129 mg, 0.34 mmol) in MeOH (10 ml) under an inert. atmosphere, was added 10%Pd/C (13 mg). H, was bubbled through the resulting suspension for 30 min. The reaction mixture was then stirred under 1 atmosphere of H, for 16 hrs. Pd/C was filtered off and the solvent removed under reduced pressure to give 2R-[3-(4-ethoxy-phenyl)-propyl]-3S-hydroxy- succinic acid diisopropyl ester (115 mg, 88% yield).
H-NMR; delta (CDCls): 7.08 (2H, d, J=8.6 Hz), 6.81 (2H, d, J=8.6), 4.97-5.14 (2H, m), 4.20 (1H, dd, J=7.3, 3.5 Hz), 4.01 (2H, q, J=7.0 Hz), 3.18 (1H, d,
J=7.3 Hz), 2.77-2.83 (1H, m), 2.55-2.62 (2H, m), 1.45-1.94 (4H, m), 1.40 (3H, t, J=7.0 Hz), 1.12-1.30 (12H, m).
LRMS: +ve ion xx (M+Na).
Step D: 2R-[3-(4-ethoxy-phenyl)-propyl]-3S-hydroxy-succinic acid.
To a solution of 2R-[3-(4-ethoxy-phenyl)-propyl]-3S-hydroxy-succinic acid diisopropyl ester (4.78 g, 12.6 mmol) in THF/water (3:1, 120 ml) was added
NaOH (1.66 g, 41.5 mmol, 5.5 eq.). The reaction mixture was then stirred for 16 hrs at RT. The mixture was concentrated under reduced pressure and acidify to pH = 3 by addition of HCI 1N. The hydroxy diacid was extracted with
AcOEt. The organic layer was dried over MgSO, and the solvent removed under reduced pressure to give the desired 2R-[3-(4-ethoxy-phenyl)-propyl}- 3S-hydroxy-succinic acid (3.66 g, 85% yield). 'H-NMR; delta (MeQD): 7.07 (2H, d, J=8.6 Hz), 6.79 (2H, d, J=8.6), 4.23 (1H, d, J=5.8 Hz), 3.98 (2H, q, J=7.0 Hz), 2.76-2.81 (1H, m), 2.53-2.59 (2H, m), 1.55-1.72 (4H, m), 1.35 (3H, t, J=7.0 Hz).
LRMS: +ve ion 319 (M+Na); -ve ion 295 (M-H).
Step E: 2R-(2,2-dimethyl-5-oxo-{1,3]dioxolan-4S-yl)-5-(4-ethoxy-phenyl)- pentanoic acid.
To a solution of 2R-[3-(4-ethoxy-phenyl)-propyl]-3S-hydroxy-succinic acid (3.66 g, 12.3 mmol) in acetone (50 mi) under an inert atmosphere were added dimethoxy propane (2.58 mi, 21 mmol, 1.7 eq.) and copper chloride (165 mg, 1.2 mmol, 0.1 eq.). The reaction mixture was stirred at RT for 16 hrs. The solvent was then removed under vacuo to give 2R-(2,2-dimethyl-5-oxo- [1,3]dioxolan-4S-yl)-5-(4-ethoxy-phenyl)-pentanoic acid (4.03 g, 97% yield). "H-NMR; delta (CDCl): 7.08 (2H, d, J=8.5 Hz), 6.82 (2H, d, J=8.5), 4.48 (1H, d, J=4.8 Hz), 4.01 (2H, q, J=7.0 Hz), 2.91-2.98 (1H, m), 2.54-2.64 (3H, m), 1.23-2.20 (4H, m), 1.58 (3H, s), 1.53 (3H, 5), 1.40 (3H, t, J=7.0 Hz).
LRMS: +ve ion 359 (M+Na); -ve ion 335 (M-H).
Step F. 2R-(2,2-dimethyl-5-oxo-[1,3]dioxolan-4S-yl)-5-(4-ethoxy-phenyl)- pentanoic acid pentafluorophenyl ester.
To a cold (OC) solution of 2R-(2,2-dimethyl-5-oxo-[1,3]dioxolan-4S-yl)-5-(4- ethoxy-phenyl)-pentanoic acid (4.03g, 12 mmol) and pentafluoro phenol (2.43 g, 13.2 mmol, 1.1 eq.) in CHCl: (50 ml) was added WSC (2.54 g, 13.2 mmol, 1.1 eq.). The reaction mixture was allowed to warm to RT ovemight. CH.Cl. was removed under vacuo and the resulting crude reaction mixture was dissolved in AcOEt (200 ml). The organic layer was washed with water (50 ml), NaHCO; sat (20 ml) and finally with brine (20 ml). Solvent was removed under reduced pressure to give an oil which was purified by flash chromatography to fumish the expected 2R-(2,2-dimethyl-5-oxo-[1,3]dioxolan- 4S-yl)-5-(4-ethoxy-phenyl)-pentanoic acid pentafluorophenyl ester (3.94 g, 65% yield). 'H-NMR; delta (CDCls): 7.09 (2H, d, J=8.4 Hz), 6.83 (2H, d, J=8.4 Hz), 4.56 (1H, d, J=6.0 Hz), 4.01 (2H, q, J=7.0 Hz), 3.20-3.28 (1H, m), 2.64 (2H, t, J= 7.6 Hz), 1.98-2.08 (2H, m), 1.70-1.86 (2H, m), 1.62 (3H, s), 1.57 (3H, s), 1.40 (8H, t, J=7.0 Hz).
Step G. 5-(4-Ethoxy-phenyl)-2R-[(2,2-dimethyl-5-oxo-[1,3]dioxolan-4S-yl)]-1- pyrrolidin-1-yl-pentan-1-one.
To a solution of 2R-(2,2-dimethyl-5-oxo-[1,3]dioxolan-4S-yl)-5-(4-ethoxy- phenyl)-pentanoic acid pentafluorophenyl ester (150 mg, 0.30 mmol) in
CHCl, (10 ml) was added pyrrolidine (30 pl, 0.36 mmol, 1.2 eq.). The reaction mixture was stirred for 16 hrs and the solvent was removed under vacuo. The crude was taken-up in AcOEt (70 ml) and washed with water (10 ml), then with NaHCO3 eat (10 ml) and finally with brine (10 mi). The solvent was dried over MgSO, and removed under reduced pressure to give the desired 5-(4-
Ethoxy-phenyl)-2R-[(2,2-dimethyl-5-oxo-[1,3]dioxolan-4S-yl)}-1-pyrrolidin-1-yl- pentan-1-one (116 mg, quant.). "H-NMR; delta (CDCls): 7.05 (2H, d, J= 8.6Hz), 6.8 (2H, d, J= 8.6Hz), 4.55 (1H, d, J= 8.4Hz), 3.99 (2H, m), 3.8-3.3 (10H, m), 3.05 (1H, m), 2.55 (2H, t, J= 7.6Hz), 2.1-1.7 (2H, m), 1.6 (3H, 8), 1.5 (3H, s), 1.4 (3H, t, J= 7.0Hz).
LRMS: +ve ion 405 (M+H), 428 (M+Na).
Step H. 6-(4-ethoxy-phenyl)-2S-hydroxy-3R-(pyrrolidine-1-carbonyl)-hexanoic acid hydroxyamide
To a solution of 5-(4-Ethoxy-phenyl)-2R-[(2,2-dimethyl-5-oxo-[1,3]dioxolan-4S- yi)}-1-pyrrolidin-1-yl-pentan-1-one (116 mg, 0.30 mmol) in <PrOH (5 ml), was added an aqueous solution of hydroxylamine (50%, 99 wl, 1.5 mmol, 5 eq.).
The reaction mixture was allowed to stir at RT for 16 hrs. The solvent was removed under reduced pressure to yield an oil which was purified by preparative reverse phase chromatography to give the required product.
H-NMR; delta (CD30D): 7.05 (2H, d, J=8.6Hz), 6.8 (2H, d, J=8.6Hz), 4.0 (4H, my), 3.85 (1H, m), 3.7 (1H, m), 3.4 (2H, m), 3.1 (1H, m), 2.55 (2H, m), 1.9-1.5 (7H, m), 1.35 (3H, t, J= 7.0Hz).
LRMS: +ve ion 387 (M+Na); -ve ion 363 (M-H)
The compounds of Examples 2-20 were prepared by the method of Example 1 by parallel synthesis, using the appropriate amine in Step G. The products were purified by preparative HPLC.
Example 2: 3R-(6,7-dimethoxy-3,4-dihydro-1H-isoquinoline-2-carbonyl)-6-(4- ethoxy-phenyl)-2S-hydroxy-hexanoic acid hydroxyamide. oo 0 >
OMe
EtO HO 0
HN OMe
OH
LRMS: +ve ion 487 (M+H), 509 (M+Na); -ve ion 485 (M-H).
Example 3: 6-(4-ethoxy-phenyl)-2S-hydroxy-3R-[4-(3-methoxy-phenyl)- piperazine-1-carbonyl]-hexanoic acid hydroxyamide.
OMe
SOO)
N N
\—/
SOT
HN
OH
LRMS: +ve ion 486 (M+H), 508 (M+Na); -ve ion 484 (M-H).
Example 4: 6-(4-ethoxy-phenyl)-2S-hydroxy-3R-[4-(4-methoxy-phenyl)- piperazine-1-carbonyl]-hexanoic acid hydroxyamide.
EO Oom \__/ ®
Beane:
HN,
OH
LRMS: +ve ion 486 (M+H), 508 (M+Na); -ve ion 484 (M-H).
Example 5: 6-(4-ethoxy-phenyl)-2S-hydroxy-3R-(4-pyridin-2-yl-piperazine-1- carbonyl)-hexanoic acid hydroxyamide.
L/\ N=
NH)
EtO HO 0)
HN_
OH
'H-NMR; delta (CD30D): 8.1 (1H, d, J= 1.4Hz), 7.55 (1H, m), 7.05 (2H, d, J= 8.7Hz), 6.9-6.6 (4H, m), 3.95 (1H, d, J= 7.0Hz), 3.55 (4H, m), 2.55 (1H, m), 1.8-1.5 (6H, m), 1.35 (3H, m).
LRMS: +ve ion 457 (M+H); -ve ion 455 (M-H).
Example 6: 6-(4-ethoxy-phenyl)-2S-hydroxy-3R-(4-pyridin-4-yl-piperazine-1- carbonyl)-hexanoic acid hydroxyamide. /~\ =
Nr
EtO HO 0
HN_
OH
Example 7: 6-(4-ethoxy-phenyl)-2S-hydroxy-3R-(morpholine-4-carbonyl)- hexanoic acid hydroxyamide. /\
N 0 —/
HN
OH
"H-NMR; delta (CDsOD): 7.05 (2H, d, J= 8.6Hz), 6.8 (2H, d, J= 8.6Hz), 4.05- 3.90 (3H, m), 3.8-3.4 (8H, m), 2.55 (2H, t, J= 6.7Hz), 1.75-1.4 (4H, m), 1.35 (3H, t, J=7.0Hz).
LRMS: +ve ion 403 (M+Na); -ve ion 379 (M-H).
Example 8: 6-(4-ethoxy-phenyl)-2S-hydroxy-3R-(2RS-methyl-morpholine-4- carbonyl)-hexanoic acid hydroxyamide.
0 {
N 0 n/
LOC
HN,
OH
LRMS: +ve ion 417 (M+Na), 395 (M+H); -ve ion 393 (M-H).
Example 9: 6-(4-ethoxy-phenyl)-2S-hydroxy-3R-(2,6-RS-dimethyl-morpholine- 4-carbonyl)-hexanoic acid hydroxyamide. 0 {
N 0 \—_—
LOC
HN_
OH
LRMS: +ve ion 431 (M+Na), 409 (M+H); -ve ion 407 (M-H).
Example 10: 6-(4-ethoxy-phenyl)-2S-hydroxy-3R-(thiomorpholine-4-carbonyl)- hexanoic acid hydroxyamide. 1 /\
N S n_/
Hoang:
HN_
OH
"H-NMR; delta (CDsOD): 7.05 (2H, d), 6.8 (2H, d), 4.0 (5H, m), 3.8-3.5 (2H, m), 2.9-2.4 (7H, m), 1.55 (4H, m) and 1.3 (3H, t).
LRMS: +ve ion 419 (M+Na). 397 (M+H); -ve ion 395 (M-H).
Example 11: 3R-(4-benzyl-piperidine-1-carbonyl)-6-(4-ethoxy-phenyl)-2S- hydroxy-hexanoic acid hydroxyamide.
DQ Ph
Oa
LOC
HN
OH
"H-NMR; delta (CD;OD): 7.3-7.0 (8H, m), 6.8 (2H, m), 4.55 (1H, d, J=12.4Hz), 4.05 (2H, dd, J=2.0Hz), 3.9 (2H, m), 2.9 (1H, m), 2.6-2.4 (5H, m), 1.84 (1H, d,
J=2.9Hz), 1.7-1.5 (6H, m), 1.35 (3H, 1, J= 7.0Hz).
LRMS: +ve ion 491 (M+Na); -ve ion 467 (M-H).
Example 12: 3R-(4-benzo[1,3]dioxol-5-yimethyl-piperazine-1-carbonyl)-6-(4- ethoxy-phenyl)-2S-hydroxy-hexanoic acid hydroxyamide. 0) 0
N N
/
Hoare
HN
OH
LRMS: +ve ion 514 (M+H); -ve ion 512 (M-H).
Example 13: 6-(4-ethoxy-phenyl)-2S-hydroxy-3R-(4-pyridin-4-ylmethyl- piperazine-1-carbonyl)-hexanoic acid hydroxyamide. /N\
N N
_/
Beane. ba
HN =N
OH
LRMS: +ve ion 471 (M+H); -ve ion 469 (M-H).
Claims (30)
1. A compound of formula (1), or an enantiomer or diastereoisomer thereof, or a salt, hydrate or solvate thereof: Ar-(Alk) NR,R, RO CONHOH (0) wherein Ar represents an optionally substituted aryl, heteroaryl, C3-Cs cycloalkyl or heterocycloakyl group; R represents hydrogen or C1-Cg alkyl, or C3-Cg cycloalkyt; Alk represents a divalent C4-Cs alkylene or C-C5 alkenylene radical; and Ri: and Rx taken together with the nitrogen atom to which they are attached form a first heterocycloalkyl ring which is optionally fused to a second C3-Cs cycloalkyl or heterocycloalkyl ring, the said first and second rings being optionally substituted by at least one group of formula (li): AK O-AkR—Z (I) wherein m, p and n are independently 0 or 1; Z represents, hydrogen, or an optionally substituted carbocyclic or heterocyclic ring of from 5 to 7 ring atoms which is optionally fused to another optionally substituted carbocyclic or heterocyclic ring of from 5 to 7 ring atoms; Alk' and Alk? independently represent optionally substituted divalent C;-C3 alkylene radicals;
X represents -O-, -S-, -S(0)-, -S(02)-, -C(=0)-, -NH-, -NR3-, -S(O2)NH-, -S(O2)NRs-, -NHS(Oz)-, or -NR3S(0Q,)-, where Ra is C4-C3 alkyl.
2. A compound as claimed in claim 1 wherein R is hydrogen.
3. A compound as claimed in claim 1 wherein R is methyl.
4, A compound as claimed in claim 1 wherein R is ethyl, n-propyl, isopropyl, n-, sec- or tert-butyl, cyclopropyl, or cyclopentyl.
5. A compound as claimed in any of the preceding claims wherein Ar is a 5- or 6- membered monocyclic aryl or heteroaryl ring, which is optionally substituted by at least one substituent selected from (C1-Cj)alkyl, (C;- Cs)alkoxy, hydroxy, hydroxy(C1-Cs)alkyl, mercapto, mercapto(C+-Cs)alkyl, (C;- Ca)alkylthio, halo, trifluoromethyl, trifluoromethoxy, nitro, nitrile (-CN), -COOH, -COOR?*, -COR?,-SO,R*, -CONH, -SO2NH,, -CONHR*, -SO,NHR, -CONR"R®, -SO.NR*R®, -NHz, -NHR*, -NR*RB, -OCONH,, -OCONHR*, -OCONR"R®, -NHCOR?*, -NHCOOR*, -NRECOOR?*, -NHSO.0R*, -NR®SO,0R", -NHCONH;, -NR*CONH,, -NHCONHRE -NRACONHRE, - NHCONR*R®, or -NRACONR*R® wherein R* and RP are independently C1-Ca alkyl, phenyl or a 5- or 6-membered monocyclic aryl or heteroaryl ring.
6. A compound as claimed in claim 5 wherein an optional substituent is in the 4- position in the case of a 6-membered ring, or in the 2- and/or 3- position in the case of a 5-membered ring.
7. A compound as claimed in any of the preceding claims wherein Ar is optionally substituted phenyl, 2-, 3-, or 4-pyridyl, 2-, or 3-thienyl, or 2-, or 3- furanyl.
8. A compound as claimed in any of the preceding claims wherein optional substituents in Ar are selected from methoxy, ethoxy,
trifluoromethoxy, methyl, ethyl, trifluoromethyl, hydroxyl, mercapto, fluoro, chloro, and bromo.
9. A compound as claimed in claim 5 wherein Ar is 4-(C,Csalkoxy)phenyi.
10. A compound as claimed in claim § wherein Ar is 4-ethoxyphenyl
11. A compound as claimed in any of the preceding claims wherein Alk is —CHg-, -CH2CH_-, -CH2CH(CHj3)-, -CHCH2CHa-, -CH,CH.CH,>CH,-, —CH=CH-, -CH,CH=CH-, -CH,CH=CHCH,-, or -CH=CHCH=CH-.
12. A compound as claimed in any of the preceding claims wherein -NR;R> forms a pyrrolidinyl, morpholyi, or thiomorpholyl ring
13. A compound as claimed in any of claims 1 to 11 wherein -NR;R; forms a piperidinyl, or piperazinyl ring
14. A compound as claimed in any of the preceding claims wherein in the group (Il), when present, p is 0, Z is hydrogen and at least one of n and m is
1.
15. A compound as claimed in any of claims 1 to 13 wherein in the group (I), when present, m, n and p are all 0 and Z is a carbocyclic or heterocyclic ring directly linked to a ring carbon or ring nitrogen of the -NR4R; group.
16. A compound as claimed in any of claims 1 to 13 wherein in the group (I), when present, p is 0, at least one of mand nis 1, and Z is a carbocyclic or heterocyclic ring linked to a ring carbon or ring nitrogen of the -NR:R: group via a C4-Cg alkylene linker between Z and the -NR;R; ring.
17. A compound as claimed in any of claims 1 to 13 wherein in the group (it), when present, pis 1.
18. A compound as claimed in claim 1 of formula (IB) or (IC) or an enantiomer or diasterecisomer thereof, or a salt, hydrate or solvate thereof: R, x ( 0) 0) N N OC, JOT R; RO CONHOH R, RO CONHOH (1B) (IC) wherein R is hydrogen or methoxy, Rj is trifluoromethyl, triflucromethoxy C;- Caalkoxy, hydroxy, or halo; Ry is (i) -SO2Rs or -CORs wherein Rs is C1-Cealkyl or phenyl or monocyclic heteroaryl having 5 or 6 ring atoms, optionally substituted by (C+-Cs)alkyl, (C-Cs)alkoxy, hydroxy, hydroxy(C-Cs)alkyl, mercapto, mercapto(C-Cs)alkyl, (C1-Cs)alkyithio, halo, trifluoromethyl, trifluoromethoxy or (ii) phenyl or monocyclic heteroaryl having 5 or 6 ring atoms; optionally substituted by (C1-Cs)alkyl, (C1-Cs)alkoxy, hydroxy, hydroxy(C1-Cs)alkyl, mercapto, mercapto(C4-Cs)alkyl, (C,-Ca)alkytthio, halo, trifluoromethyl, trifluoromethoxy.
19. A compound as claimed in claim 18 wherein a heteroaryl ring forming part of Rs is pyridyl, pyrimidinyl, triazinyl, thienyl, or furanyl.
20. A compound as claimed in any of the preceding claims having the stereochemical configuration shown in formula (1A): Ar-(Alk) NR,R, RO CONHOH (1A)
21. A compound as claimed in claim 1, which is selected from the group consisting of: 6-(4-ethoxy-pheny!)-2S-hydroxy-3R-(pyrrolidine-1-carbonyl)-hexanoic acid hydroxyamide. 3R-(8,7-dimethoxy-3,4-dihydro-1H-isoquinoline-2-carbonyl)-6-(4-ethoxy- phenyl)-2S-hydroxy-hexanoic acid hydroxyamide. 6-(4-ethoxy-phenyl)-2S-hydroxy-3R-[4-(3-methoxy-phenyl)-piperazine-1- carbonyl]-hexanoic acid hydroxyamide. 6-(4-ethoxy-phenyl)-2S-hydroxy-3R-[4-(4-methoxy-phenyl)-piperazine-1- carbonyl]-hexanoic acid hydroxyamide. 6-(4-ethoxy-phenyl)-2S-hydroxy-3R-(4-pyridin-2-yl-piperazine-1-carbonyl)- hexanoic acid hydroxyamide. 6-(4-ethoxy-phenyl)-2S-hydroxy-3R-(4-pyridin-4-yl-piperazine-1-carbonyl)- hexanoic acid hydroxyamide. 6-(4-ethoxy-phenyl)-2S-hydroxy-3R-(morpholine-4-carbonyl)-hexanoic acid hydroxyamide. 6-(4-ethoxy-phenyl)-2S-hydroxy-3R-(2RS-methyl-morpholine-4-carbonyl)- hexanoic acid hydroxyamide. 6-(4-ethoxy-phenyl)-2S-hydroxy-3R-(2,6-RS-dimethyl-morpholine-4-carbonyi)- hexanoic acid hydroxyamide. 6-(4-ethoxy-phenyl)-2S-hydroxy-3R-(thiomorpholine-4-carbonyl)-hexanoic acid hydroxyamide. 3R-(4-benzyl-piperidine-1-carbonyl)-6-(4-ethoxy-phenyl)-2S-hydroxy-hexanoic acid hydroxyamide.
3R-(4-benzo[1,3]dioxol-5-ylmethyl-piperazine-1-carbonyl)-6-(4-ethoxy- phenyl)-2S-hydroxy-hexanoic acid hydroxyamide. 6-(4-ethoxy-phenyl)-2S-hydroxy-3R-(4-pyridin-4-yimethyl-piperazine-1- carbonyl)-hexanoic acid hydroxyamide. 6-(4-ethoxy-phenyl)-2S-hydroxy-3R-(4-benzylpiperazine-1-carbonyl)-hexanoic acid hydroxyamide. 6-(4-ethoxy-phenyl)-2S-hydroxy-3R-(4-pyrimidin-2-yl-piperazine-1-carbonyl)- hexanoic acid hydroxyamide. 6-(4-ethoxy-phenyl)-2S-hydroxy-3R-[4-(4-trifluoromethyi-pyrimidin-2-yi)- piperazine-1-carbonyl]-hexanoic acid hydroxyamide. 6-(4-ethoxy-phenyl)-2S-hydroxy-3R-[4-(4-chioro-pyrimidin-2-yl)-pipe razine-1- carbonyl}-hexanoic acid hydroxyamide. 3R-[4-(4,6-dimethoxy-[1,3,5}triazin-2-yl)-piperazine-1 -carbonyl]-6-(4-ethoxy- phenyl)-2S-hydroxy-hexanoic acid hydroxyamide. 6-(4-ethoxy-phenyi)-2S-hydroxy-3 R-{4-(3-trifluoromethyl-phenyl)-piperazine-1- carbonyl]-hexanoic acid hydroxyamide. 6-(4-ethoxy-phenyl)-2S-hydroxy-3R-[4-(2-fluoro-phenyi)-piperazine-1- carbonyl}-hexanoic acid hydroxyamide. 3R-[4-(acetyl-methyl-amino)-piperidine-1 -carbonyl]-6-(4-ethoxy-phenyl)-2S- hydroxy-hexanoic acid hydroxyamide. 6-(4-ethoxy-phenyl)-2S-hydroxy-3R-[4-(methyi-propyl-amino)-piperidine-1 - carbonyl]-hexanoic acid hydroxyamide.
6-(4-ethoxy-phenyl)-2S-hydroxy-3R-(3S-benzyl-morpholine-4-carbonyl)- hexanoic acid hydroxyamide. 6-(4-sethoxy-phenyl)-2S-hydroxy-3R-(3S-isobutyl-morpholine-4-carbonyl)- hexanoic acid hydroxyamide. 6-(4-ethoxy-phenyl)-2S-hydroxy-3R-(3S-phenyl-morpholine-4-carbonyl)- hexanoic acid hydroxyamide. 3R-(4-benzyl-3RS-methyl-piperazine-1-carbonyl)-6-(4-ethoxy-phenyl)-2S- hydroxy-hexanoic acid hydroxyamide. 3R-(3S,4-dibenzyl-piperazine-1-carbonyl)-6-(4-ethoxy-phenyl)-2S-hydroxy- hexanoic acid hydroxyamide. 3R-(4-benzyl-3RS-phenyl-piperazine-1-carbonyl)-6-(4-ethoxy-phenyt)-2S- hydroxy-hexanoic acid hydroxyamide. 4-(4-benzo[1,3]dioxol-5-yimethyl-piperazin-1-yl)-2S,N-dihydroxy-4-oxo-3R-(4- trifluoromethoxy-benzyl)-butyramide. 3R-benzyl-2S,N-dihydroxy-4-morpholin-4-yi-4-oxo-butyramide.
3R-(4-Benzyloxy-benzyl)-2S,N-dihydroxy-4-oxo-4-piperidin-1-yl-butyramide. 2S,N-dihydroxy-3R-(4-hydroxy-benzyl)-4-oxo-4-piperidin-1-yl-butyramide. 4-(4-benzo[1,3]dioxol-5-yimethyl-piperazin-1-yl)-3R-(4-benzyloxy-benzyl)-
25,N-dihydroxy-4-oxo-butyramide. 6-(3,5-bis-trifluoromethyl-phenyl)-2S-hydroxy-3R-(morpholine-4-carbonyl)- hexanoic acid hydroxyamide.
3R-(4-benzyl-piperidine-1-carbonyl)-6-(3,5-bis-trifluoromethyl-phenyl)-2S- hydroxy-hexanoic acid hydroxyamide. 6-(3,5-bis-trifluoromethyl-phenyl)-2S-hydroxy-3R-(4-pyridin-2-yl-piperazine-1- carbonyl)-hexanoic acid hydroxyamide. 6-(3,5-bis-trifluoromethyl-phenyl)-3R-(6,7-dimethoxy-3,4-dihydro-1H- isoquinoline-2-carbonyl)-2S-hydroxy-hexanoic acid hydroxyamide. 6-(3,5-bis-trifluoromethyl-phenyl)-2S-hydroxy-3R-(pyrrolidine-1-carbonyl)- hexanoic acid hydroxyamide 3R-(2S-benzyi-4-methyl-piperazine-1-carbonyl)-6-(4-ethoxy-phenyl)-2S- hydroxy-hexanoic acid hydroxyamide. 6-(4-ethoxy-phenyl)-2S-hydroxy-3R-[4-(4-trifluoromethoxy-benzenesulfonyl)- piperazine-1-carbonyl}-hexanoic acid hydroxyamide. 6-(4-ethoxy-phenyl)-2S-hydroxy-3R-{4-(toluene-4-sulfonyl)-piperazine-1- carbonyl}-hexanoic acid hydroxyamide. 3R-[4-(5-bromo-thiophene-2-sulfonyl)-piperazine-1-carbonyl]-6-(4-ethoxy- phenyl)-2S-hydroxy-hexanoic acid hydroxyamide. 3R-[4-(5-benzenesulfonyl-thiophene-2-sulfonyl)-piperazine-1-carbonyi}-6-(4- ethoxy-phenyl)-2S-hydroxy-hexanoic acid hydroxyamide. 3R-[4-(4-butoxy-benzenesulfonyl)-piperazine-1-carbonyl]-6-(4-ethoxy-phenyl)- 2S-hydroxy-hexanoic acid hydroxyamide. 6-(4-ethoxy-phenyl)-2S-hydroxy-3R-[4-(4-methoxy-2,3,6-trimethyl- benzenesulfonyl)-piperazine-1-carbonyl]-hexanoic acid hydroxyamide.
3R-{4-(3,4-dimethoxy-benzenesulfonyl)-piperazine-1-carbonyi]-6-(4-ethoxy- phenyl)-2S-hydroxy-hexanoic acid hydroxyamide. 6-(4-methoxy-phenyl)-2S-hydroxy-3R-[4-(2-fluoro-phenyl)-piperazine-1- carbonyl]-hexanoic acid hydroxyamide. 6-(4-methoxy-phenyl)-2S-hydroxy-3R-(4-pyridin-2-yl-piperazine-1-carbonyl)- hexanoic acid hydroxyamide. - 6-(4-fluoro-phenyl)-3R-[4-(2-fluoro-phenyl)-piperazine-1-carbonyl]-2S- hydroxy-hexanoic acid hydroxyamide. 6-(4-fluoro-phenyl)-2S-hydroxy-3R-(4-pyridin-2-yl-piperazine-1-carbonyl)- hexanoic acid hydroxyamide. 3R-(4-benzyl-2S-methyl-piperazine-1-carbonyl)-6-(4-ethoxy-phenyl)-2S- hydroxy-hexanoic acid hydroxyamide. 3R-(4-benzyl-2S5-methyl-piperazine-1-carbonyl)-6-(4-methoxy-phenyl)-2S- hydroxy-hexanoic acid hydroxyamide. 3R-(4-benzyl-2S-i-butyl-piperazine-1-carbonyl)-6-(4-methoxy-phenyl)-2S- hydroxy-hexanoic acid hydroxyamide. 3R-(4-benzyl-2S-methyl-piperazine-1-carbonyl)-6-(4-fluoro-phenyl)-2S- hydroxy-hexanoic acid hydroxyamide. 3R-(4-benzyl-28-i-butyl-piperazine-1-carbonyl)-6-(4-fluoro-phenyl)-2S- hydroxy-hexanoic acid hydroxyamide. 4-[5-(4-ethoxy-phenyl)-2R-(1S-hyd roxy-hydroxycarbamoyl-methyl)-pentanoyl]- 2S-methyi-piperazine-1-carboxylic acid tert-butyl ester.
26. A method as claimed in claim 24 or a use as claimed in claim 25 wherein the disease or condition is bone resorption, tumour growth or invasion by secondary metastases; rheumatoid arthritis, septic arthritis, osteoarthritis, periodontitis, gingivitis, corneal ulceration, cardiac hypertrophy, acute respiratory distress syndrome, neuroinflammatory disorders, e.g. multiple sclerosis; restenosis; emphysemia; fibrotic didease e.g. fibrosis post radiotherapy, kerotid scarring, liver fibrosis and cystic fibrosis; chronic obstructive pulmonary disease; bronchitis; asthma; autoimmune disease; transplant rejection (e.g. graft versus host disease); cystic fibrosis; psoriasis; psoriatic arthritis; degenerative cartilage loss; inflammatory gastric conditions,
e.g. Crohn's disease, inflammatory bowel disease, and ulcerative colitis; atopic dermatitis, epidermolysis bullosa; epidermic ulceration; a neuropathy or nephropathy e.g.interstitial nephritis, glomerulonephriris or renal failure; ocular inflammation; liver cirrhosis, Sjoegren’s syndrome; or an inflammatory condition of the nervous system.
27. A method as claimed in claim 24 or a use as claimed in claim 25 wherein the disease or condition is fibrotic disease, multiple sclerosis, emphysemia, bronchitis or asthma.
28. A method of preparing metalloproteinase inhibitors of formula (IA) according to any of claims 1 to 21 wherein R is hydrogen, comprising the de- protection and/or transformation step of: Oo Ar-(Alk) vou J NR,R, NR,R, x HO CONHOH Je (1A)
(m.) wherein Ar, Alk, Ry and R; are as defined in any of claims 1 to 16.
29. A compound of formula (IIB)
0] Ar-(Alk) NR,R, Q Oo Ad (1B) wherein Ar, Alk, Ry and R; are as defined in any of claims 1 to 19.
30. A process for the preparation of a compound as claimed in claim 29 comprising comprising the step of reacting a compound of formula (ill) Ar-(Alk) COOH x (mn i with a cyclic amine HNR;R.., wherein Ar, Alk, Ry and R; are as defined in any of claims 1 to 19.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB0319917A GB0319917D0 (en) | 2003-08-23 | 2003-08-23 | Metalloproteinase inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA200602358B true ZA200602358B (en) | 2007-09-26 |
Family
ID=28460251
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA200602358A ZA200602358B (en) | 2003-08-23 | 2006-03-22 | Derivatives of hydroxamic acid as metalloproteinase inhibitors |
Country Status (4)
| Country | Link |
|---|---|
| CN (1) | CN1930139B (en) |
| ES (1) | ES2365731T3 (en) |
| GB (1) | GB0319917D0 (en) |
| ZA (1) | ZA200602358B (en) |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9501737D0 (en) * | 1994-04-25 | 1995-03-22 | Hoffmann La Roche | Hydroxamic acid derivatives |
| US5703092A (en) * | 1995-04-18 | 1997-12-30 | The Dupont Merck Pharmaceutical Company | Hydroxamic acid compounds as metalloprotease and TNF inhibitors |
| US5917090A (en) * | 1995-06-30 | 1999-06-29 | British Biotech Pharmaceuticals Ltd. | Matrix metalloproteinase inhibitors |
| GB9804504D0 (en) * | 1998-03-03 | 1998-04-29 | Leo Pharm Prod Ltd | Matrix metalloproteinase inhibitors |
| JP2003534239A (en) * | 1999-12-17 | 2003-11-18 | ヴァージコア・インコーポレーテッド | Novel succinate compounds, compositions, and methods of use and preparation |
| EP1406893B1 (en) * | 2001-06-15 | 2007-04-18 | Vicuron Pharmaceuticals, Inc. | Pyrrolidine bicyclic compounds |
-
2003
- 2003-08-23 GB GB0319917A patent/GB0319917D0/en not_active Ceased
-
2004
- 2004-08-18 CN CN2004800237488A patent/CN1930139B/en not_active Expired - Fee Related
- 2004-08-18 ES ES04768117T patent/ES2365731T3/en not_active Expired - Lifetime
-
2006
- 2006-03-22 ZA ZA200602358A patent/ZA200602358B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| GB0319917D0 (en) | 2003-09-24 |
| CN1930139B (en) | 2011-07-27 |
| CN1930139A (en) | 2007-03-14 |
| ES2365731T3 (en) | 2011-10-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2768554B2 (en) | Hydroxamic acid derivatives as metalloproteinase inhibitors | |
| ES2325140T3 (en) | AMIDAS REPLACED WITH HETEROCICLES AS INHIBITORS OF THE CALPAINA. | |
| US6218389B1 (en) | Acyclic metalloprotease inhibitors | |
| US6201133B1 (en) | Certain cyclic thio substituted acylaminoacid amide derivatives | |
| US8288541B2 (en) | Piperazine amide derivatives | |
| US20100280018A1 (en) | Derivatives Of Hydroxamic Acid As Metalloproteinase Inhibitors | |
| JP2002512220A (en) | Substituted benzamides, their preparation and use as inhibitors of cysteine protease | |
| WO2012119941A1 (en) | Peptidyl nitrilcompounds as peptidase inhibitors | |
| US6825354B2 (en) | Alkynyl containing hydroxamic acid compounds as matrix metalloproteinase and TACE inhibitors | |
| WO2011145669A1 (en) | Amide derivative | |
| EP1147080B1 (en) | Alkynyl containing hydroxamic acid compounds as tace inhibitors | |
| US6812237B2 (en) | N-substituted peptidyl nitriles as cysteine cathepsin inhibitors | |
| ZA200602358B (en) | Derivatives of hydroxamic acid as metalloproteinase inhibitors | |
| US8227492B2 (en) | Sulfoxamine derivatives as factor Xa inhibitors | |
| KR20020038951A (en) | Beta disubstituted metalloprotease inhibitors | |
| EP1283825B1 (en) | N-substituted peptidyl nitriles as cysteine cathepsin inhibitors | |
| MXPA06001865A (en) | Derivatives of hydroxamic acid as metalloproteinase inhibitors | |
| US6248743B1 (en) | Butadiene derivatives and process for preparing thereof |